# data[].attributes.title
Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders

# data[].attributes.body.value
The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated:

increased activity

lower toxicity

greater stability

longer half-life

These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.

NIA is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives.  In addition, NIA is open to collaborative research relationships (such as under a CRADA) whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions.  In addition, NIA is open to a wide variety of licensing arrangements with respect to these technologies.

Competitive Advantages:

Ability to readily cross the blood-brain barrier

Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain

Substantial intellectual property life cycle: e.g., patents if issued likely will expire no earlier than 2038

Proof-of-concept in rat model

Commercial Applications:

Therapies to treat:

Autoimmune disorders

Inflammation

Pain-related disorders

Itching and/or skin disorders

# data[].attributes.body.processed
The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated:

increased activity

lower toxicity

greater stability

longer half-life

These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.

NIA is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives.  In addition, NIA is open to collaborative research relationships (such as under a CRADA) whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions.  In addition, NIA is open to a wide variety of licensing arrangements with respect to these technologies.

Competitive Advantages:

Ability to readily cross the blood-brain barrier

Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain

Substantial intellectual property life cycle: e.g., patents if issued likely will expire no earlier than 2038

Proof-of-concept in rat model

Commercial Applications:

Therapies to treat:

Autoimmune disorders

Inflammation

Pain-related disorders

Itching and/or skin disorders

# data[].attributes.field_licensingcontact_hrefs[]
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Jinnah, Zarpheen
zarpheen.jinnah@nih.gov

# data[].attributes.field_licensing_contacts[].value
Jinnah, Zarpheen
zarpheen.jinnah@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Jinnah, Zarpheen
zarpheen.jinnah@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/529,846
Filed on 2017-07-07
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/529,846
Filed on 2017-07-07
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2018/041086
Filed on 2018-07-06
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2018/041086
Filed on 2018-07-06
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2018297192
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].processed
Australia
National Stage 2018297192
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].value
Canada
National Stage 3064132
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].processed
Canada
National Stage 3064132
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].value
China
National Stage 201880045287.6
Filed on 2018-07-06
Status: Abandoned

# data[].attributes.field_patents[].processed
China
National Stage 201880045287.6
Filed on 2018-07-06
Status: Abandoned

# data[].attributes.field_patents[].value
European Patent
National Stage 18746415.1
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 18746415.1
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].value
Japan
National Stage 2019-572570
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].processed
Japan
National Stage 2019-572570
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].value
South Korea
National Stage 10-2020-7003568
Filed on 2020-02-06
Status: Issued

# data[].attributes.field_patents[].processed
South Korea
National Stage 10-2020-7003568
Filed on 2020-02-06
Status: Issued

# data[].attributes.field_patents[].value
Mexico
National Stage MX/a/2019/015730
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].processed
Mexico
National Stage MX/a/2019/015730
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].value
US Patent 11,555,021
Filed on 2019-12-30
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 11,555,021
Filed on 2019-12-30
Status: Issued

# data[].attributes.field_patents[].value
Hong Kong
National Stage 62020007841.3
Filed on 2018-07-06
Status: Pending

# data[].attributes.field_patents[].processed
Hong Kong
National Stage 62020007841.3
Filed on 2018-07-06
Status: Pending

# data[].attributes.field_patents[].value
US Patent 12,479,812
Filed on 2022-04-12
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 12,479,812
Filed on 2022-04-12
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 18746415.1
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 18746415.1
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/529,846
Filed on 2017-07-07
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2018/041086
Filed on 2018-07-06
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2018297192
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3064132
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patent_htmls[]
China
National Stage 201880045287.6
Filed on 2018-07-06
Status: Abandoned

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 18746415.1
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2019-572570
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patent_htmls[]
South Korea
National Stage 10-2020-7003568
Filed on 2020-02-06
Status: Issued

# data[].attributes.field_patent_htmls[]
Mexico
National Stage MX/a/2019/015730
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 11,555,021
Filed on 2019-12-30
Status: Issued

# data[].attributes.field_patent_htmls[]
Hong Kong
National Stage 62020007841.3
Filed on 2018-07-06
Status: Pending

# data[].attributes.field_patent_htmls[]
US Patent 12,479,812
Filed on 2022-04-12
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 18746415.1
Filed on 2018-07-06
Status: Issued

# data[].attributes.field_publications[].value
Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch.

# data[].attributes.field_publications[].processed
Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch.

# data[].attributes.field_technology_names[]
Synthesis And Use Of Endogenous Lipid Mediators, Their Stable Analogs, And Small Molecule Pharmacophores Containing The Same Active Moieties As The Endogenous Compounds, To Regulate Inflammation, Neuronal Activation, Nociceptive And Pruriceptive Sens

# data[].attributes.body.value
Summary:

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system with particle identification capabilities.

Description of Technology:

Autoradiography is a photographic process that exposes a medium, sensitive to radiation, to a sample emitting radiation. The current state of the art involves exposing a thin slice of tissue to an ionization-sensitive film for several hours or days and then scanning the film into an autoradiography image. This image is created using the sum of the ionizations from all the decays that occurred during the time of exposure on the ionization-sensitive medium. Imaging quality of these samples can be improved by collecting information from each individual decay to enhance the autoradiographic measurement.

Researchers at National Cancer Institute (NCI) developed a Quantitative Particle Identification (QPID) digital autoradiography system to measure the energy deposition from charged particles for each individual radioactive decay. The QPID leverages the ionizing radiation detection features of the Timepix3 detector to generate autoradiograph images in units of dose per unit time and area. The high readout speed of the Timepix3 gives the detector the capability to measure separate decay ionizations. It also segregates the image into one generated only by alpha and the other only by beta particles. A gamma detector was interfaced with the Timepix3 – allowing tagging charged particle ionization events in coincidence with a gamma emission during the isotope decay. This allows for a method to distinguish between alpha and positron emitting radioisotopes when imaged concurrently in the same pathology sample. This is the most unique feature of the QPID which will aid the development of new theranostic treatments in which two similar ligands are used.

Researchers at the NCI seek licensing and/or co-development research collaborations to continue developing the QPID system for improved autoradiography imaging.

Potential Commercial Applications:

Improved radiotherapy dosing for cancer treatment

Improved radiotherapy guidance for cancer treatment

Improve accuracy of biopsy procedures through real-time tracer measurement and detection

Measuring dual radioligand pathology samples

Competitive Advantages:

QPID can measure charge particle activity for individual decays (alpha, beta, and gamma)

QPID measures absolute time of decay relative to the start of data acquisition

QPID more accurately measures radioactive dose in a tissue sample

The figure shows the unique ability of the QPID to image two radioisotopes simultaneously. A mouse was injected with a mixture of 223RaCl and Na18F, a theranostic agent pair which treats and images bone metastasis from prostate cancer. An hour after injection, a 50 micron thick spine sample was imaged on the QPID. The 223RaCl and Na18F uptake into the bone was separated into two images, one as the distribution of 223RaCl and the other as the distribution of Na18F. Because the QPID records individual decays of either radioisotope, accurate amounts of the two radioisotopes can be measured and studies of the biodistribution and micro-dosimetry are possible. The top row (panels a, b, and c) are autoradiography images generated by the QPID. The bottom row (panels d, e and f) are co-registered images of photographs of the sample overlayed  with the radioisotope distribution.

# data[].attributes.body.processed
Summary:

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system with particle identification capabilities.

Description of Technology:

Autoradiography is a photographic process that exposes a medium, sensitive to radiation, to a sample emitting radiation. The current state of the art involves exposing a thin slice of tissue to an ionization-sensitive film for several hours or days and then scanning the film into an autoradiography image. This image is created using the sum of the ionizations from all the decays that occurred during the time of exposure on the ionization-sensitive medium. Imaging quality of these samples can be improved by collecting information from each individual decay to enhance the autoradiographic measurement.

Researchers at National Cancer Institute (NCI) developed a Quantitative Particle Identification (QPID) digital autoradiography system to measure the energy deposition from charged particles for each individual radioactive decay. The QPID leverages the ionizing radiation detection features of the Timepix3 detector to generate autoradiograph images in units of dose per unit time and area. The high readout speed of the Timepix3 gives the detector the capability to measure separate decay ionizations. It also segregates the image into one generated only by alpha and the other only by beta particles. A gamma detector was interfaced with the Timepix3 – allowing tagging charged particle ionization events in coincidence with a gamma emission during the isotope decay. This allows for a method to distinguish between alpha and positron emitting radioisotopes when imaged concurrently in the same pathology sample. This is the most unique feature of the QPID which will aid the development of new theranostic treatments in which two similar ligands are used.

Researchers at the NCI seek licensing and/or co-development research collaborations to continue developing the QPID system for improved autoradiography imaging.

Potential Commercial Applications:

Improved radiotherapy dosing for cancer treatment

Improved radiotherapy guidance for cancer treatment

Improve accuracy of biopsy procedures through real-time tracer measurement and detection

Measuring dual radioligand pathology samples

Competitive Advantages:

QPID can measure charge particle activity for individual decays (alpha, beta, and gamma)

QPID measures absolute time of decay relative to the start of data acquisition

QPID more accurately measures radioactive dose in a tissue sample

The figure shows the unique ability of the QPID to image two radioisotopes simultaneously. A mouse was injected with a mixture of 223RaCl and Na18F, a theranostic agent pair which treats and images bone metastasis from prostate cancer. An hour after injection, a 50 micron thick spine sample was imaged on the QPID. The 223RaCl and Na18F uptake into the bone was separated into two images, one as the distribution of 223RaCl and the other as the distribution of Na18F. Because the QPID records individual decays of either radioisotope, accurate amounts of the two radioisotopes can be measured and studies of the biodistribution and micro-dosimetry are possible. The top row (panels a, b, and c) are autoradiography images generated by the QPID. The bottom row (panels d, e and f) are co-registered images of photographs of the sample overlayed  with the radioisotope distribution.

# data[].attributes.field_collaboration_description.value
Researchers at the NCI seek licensing and/or co-development research collaborations  for developing the QPID system for improved autoradiography imaging.

# data[].attributes.field_collaboration_description.processed
Researchers at the NCI seek licensing and/or co-development research collaborations  for developing the QPID system for improved autoradiography imaging.

# data[].attributes.field_licensingcontact_htmls[]
Cheng, Eric
eric.cheng2@nih.gov

# data[].attributes.field_licensing_contacts[].value
Cheng, Eric
eric.cheng2@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Cheng, Eric
eric.cheng2@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/651,184
Filed on 2024-05-23
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/651,184
Filed on 2024-05-23
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/028714
Filed on 2025-05-09
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/028714
Filed on 2025-05-09
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/651,184
Filed on 2024-05-23
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/028714
Filed on 2025-05-09
Status: Pending

# data[].attributes.field_publications[].value
Adler SS, et al. A Quantitative Particle Identification (QPID) spectral autoradiography system. (PMID40374923)

# data[].attributes.field_publications[].processed
Adler SS, et al. A Quantitative Particle Identification (QPID) spectral autoradiography system. (PMID40374923)

# data[].attributes.field_technology_names[]
Quantitative Particle Identification (QPID) Digital Autoradiography System
Leidos EIR # 23-008

# data[].attributes.title
Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin

# data[].attributes.body.value
Summary:

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.

Description of Technology:

Mesothelin (MSLN) is a surface antigen highly expressed in many solid tumors, such as mesothelioma, ovarian, and pancreatic cancers. MSLN is present at relatively low levels in mesothelial cells of healthy individuals, making it an ideal candidate for targeted therapeutics. However, the efficacy of MSLN-targeted agents is often reduced as a portion of the protein is shed from the cell surface and binds to available anti-MSLN antibodies. This reduces therapeutic engagement at the cell surface as shed MSLN acts as a decoy within tumor microenvironments, limiting antibodies from reaching and destroying tumor cells.

Researchers at National Cancer Institute (NCI) developed a novel mAb, RO4, which specifically binds to the juxta-membrane region of MSLN to block shedding. RO4 binds to the same region of MSLN as a previously developed mAb, 15B6 (NCI Ref. #E-106-2017), but in a different conformation. This allows for increased binding affinity and specificity. CAR-T cells made with humanized RO4 demonstrated higher cytotoxicity both in vitro and in vivo compared to h15B6 CAR-Ts. Additionally, hRO4 exhibited broader binding across MSLN-positive cell types compared to h15B6, suggesting wider utility in patient populations.

Researchers at the NCI seek licensing and/or co-development research collaborations for further development of RO4 that can be used to treat MSLN-positive cancers.

Potential Commercial Applications:

Treatment of various MSLN-positive cancers – including mesothelioma, ovarian and pancreatic cancer

Development of CAR T cells and bispecific antibodies to target MSLN and CD3

Development of Antibody-Drug Conjugates (ADCs) and Antibody-nanoparticle conjugates to deliver cytotoxic payloads to MSLN-positive tumors

Competitive Advantages:

Increased therapeutic effectiveness via avoiding shed decoy interference

Enhanced binding affinity and selectivity compared to earlier antibodies

Improved cytotoxicity across various MSLN-positive tumors

Versatility in use of CAR T cells and bispecific antibodies targeting MSLN and CD3

# data[].attributes.body.processed
Summary:

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.

Description of Technology:

Mesothelin (MSLN) is a surface antigen highly expressed in many solid tumors, such as mesothelioma, ovarian, and pancreatic cancers. MSLN is present at relatively low levels in mesothelial cells of healthy individuals, making it an ideal candidate for targeted therapeutics. However, the efficacy of MSLN-targeted agents is often reduced as a portion of the protein is shed from the cell surface and binds to available anti-MSLN antibodies. This reduces therapeutic engagement at the cell surface as shed MSLN acts as a decoy within tumor microenvironments, limiting antibodies from reaching and destroying tumor cells.

Researchers at National Cancer Institute (NCI) developed a novel mAb, RO4, which specifically binds to the juxta-membrane region of MSLN to block shedding. RO4 binds to the same region of MSLN as a previously developed mAb, 15B6 (NCI Ref. #E-106-2017), but in a different conformation. This allows for increased binding affinity and specificity. CAR-T cells made with humanized RO4 demonstrated higher cytotoxicity both in vitro and in vivo compared to h15B6 CAR-Ts. Additionally, hRO4 exhibited broader binding across MSLN-positive cell types compared to h15B6, suggesting wider utility in patient populations.

Researchers at the NCI seek licensing and/or co-development research collaborations for further development of RO4 that can be used to treat MSLN-positive cancers.

Potential Commercial Applications:

Treatment of various MSLN-positive cancers – including mesothelioma, ovarian and pancreatic cancer

Development of CAR T cells and bispecific antibodies to target MSLN and CD3

Development of Antibody-Drug Conjugates (ADCs) and Antibody-nanoparticle conjugates to deliver cytotoxic payloads to MSLN-positive tumors

Competitive Advantages:

Increased therapeutic effectiveness via avoiding shed decoy interference

Enhanced binding affinity and selectivity compared to earlier antibodies

Improved cytotoxicity across various MSLN-positive tumors

Versatility in use of CAR T cells and bispecific antibodies targeting MSLN and CD3

# data[].attributes.field_collaboration_description.value
Researchers at the NCI seek licensing and/or co-development research collaborations for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.

# data[].attributes.field_collaboration_description.processed
Researchers at the NCI seek licensing and/or co-development research collaborations for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.

# data[].attributes.field_licensingcontact_hrefs[]
greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin&body=Please send me information about technology [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Greene, Jaime
greenejaime@mail.nih.gov

# data[].attributes.field_licensing_contacts[].value
Greene, Jaime
greenejaime@mail.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Greene, Jaime
greenejaime@mail.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin&body=Please send me information about technology [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/550,703
Filed on 2024-02-07
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/550,703
Filed on 2024-02-07
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/014973
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/014973
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3315513
Filed on 2026-06-17
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3315513
Filed on 2026-06-17
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].value
European Patent
National Stage 25708322.0
Filed on 2026-06-23
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 25708322.0
Filed on 2026-06-23
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2025218272
Filed on 2026-06-05
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2025218272
Filed on 2026-06-05
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/550,703
Filed on 2024-02-07
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/014973
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3315513
Filed on 2026-06-17
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 25708322.0
Filed on 2026-06-23
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2025218272
Filed on 2026-06-05
Status: Pending

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF (RO4 antibody)

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF (R04 antibody)

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES THAT BIND THE JUXTAMEMBRANE REGION OF MESOTHELIN AND USES THEREOF

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF (R04 antibody)

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES THAT BIND THE JUXTAMEMBRANE REGION OF MESOTHELIN AND USES THEREOF

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF (R04 antibody)

# data[].attributes.field_publications[].value
Onda M, et al. RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy. (PMID41550974)

# data[].attributes.field_publications[].processed
Onda M, et al. RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy. (PMID41550974)

# data[].attributes.field_publications[].value
Liu X, et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. (PMID35512094)

# data[].attributes.field_publications[].processed
Liu X, et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. (PMID35512094)

# data[].attributes.field_related_inventions[].processed
E-106-2017

# data[].attributes.field_related_inventions[].processed
E-033-2022

# data[].attributes.field_technology_names[]
Monoclonal Antibody R04 that Reacts with the Juxta-membrane Region of Mesothelin

# data[].attributes.title
Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)

# data[].attributes.body.value
The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity.

Because the noroviruses cannot be propagated by any means in the laboratory, an important strategy in their study is the development of molecular biology-based tools. This invention reports the development of recombinant baculoviruses carrying the capsid gene from several caliciviruses associated with human disease. Growth of these baculovirus recombinants in insect cells results in the expression of virus-like particles (VLPs) that are antigenically indistinguishable from the native calicivirus particle. These VLPs can be purified in large quantities for use as diagnostic reagents and potential vaccine candidates.

# data[].attributes.body.processed
The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity.

Because the noroviruses cannot be propagated by any means in the laboratory, an important strategy in their study is the development of molecular biology-based tools. This invention reports the development of recombinant baculoviruses carrying the capsid gene from several caliciviruses associated with human disease. Growth of these baculovirus recombinants in insect cells results in the expression of virus-like particles (VLPs) that are antigenically indistinguishable from the native calicivirus particle. These VLPs can be purified in large quantities for use as diagnostic reagents and potential vaccine candidates.

# data[].attributes.field_collaboration_description.value
The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize norovirus VLP antigens. Please contact Kim Y. Green at kgreen@niaid.nih.gov for more information.

# data[].attributes.field_collaboration_description.processed
The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize norovirus VLP antigens. Please contact Kim Y. Green at kgreen@niaid.nih.gov for more information.

# data[].attributes.field_license_status.value
The materials embodied in this invention are available nonexclusively through a biological materials license.

# data[].attributes.field_license_status.processed
The materials embodied in this invention are available nonexclusively through a biological materials license.

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12).

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12).

# data[].attributes.field_publications[].value
Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly.

# data[].attributes.field_publications[].processed
Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly.

# data[].attributes.field_related_inventions[].processed
E-283-2003-0

# data[].attributes.field_related_inventions[].processed
E-214-2003-0

# data[].attributes.field_related_inventions[].processed
E-212-2003-0

# data[].attributes.field_technology_names[]
Construction Of Recombinant Baculoviruses Carrying The Gene Encoding The Major Capsid Protein, VP1, From Calicivirus Strains (including, But Not Limited To, Norovirus Strains, Toronto, Hawaii, Desert Shield, Snow Mountain And MD145-12)

# data[].attributes.body.value
Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.

Researchers at NIAID’s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.

These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.

# data[].attributes.body.processed
Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.

Researchers at NIAID’s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.

These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov.

# data[].attributes.field_commercial_applications.value
Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10.

# data[].attributes.field_commercial_applications.processed
Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10.

# data[].attributes.field_competitive_advantages.value
Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature.

No low-grade, transient fever observed compared with prior candidates.

Flexible reassortant design that may support addition of newly important rotavirus serotypes.

# data[].attributes.field_competitive_advantages.processed
Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature.

No low-grade, transient fever observed compared with prior candidates.

Flexible reassortant design that may support addition of newly important rotavirus serotypes.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patents[].processed
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.title
Novel Antibody Test for Mycoplasma Detection

# data[].attributes.body.value
The technology is a novel antibody test designed for the detection of Mycoplasma antibodies, representing a significant advancement in Mycoplasma detection methods. This test offers a rapid and reliable means of diagnosing Mycoplasma infections, which is particularly valuable in research and clinical settings. Unlike existing tests, this innovative approach provides specificity and sensitivity in detecting Mycoplasma antibodies, ensuring accurate and timely diagnosis. The technology's development stage is currently at the prototype phase, indicating that it is undergoing initial testing and refinement to optimize its performance. Once fully developed, this antibody test has the potential to revolutionize Mycoplasma detection, improving research outcomes and patient care.

# data[].attributes.body.processed
The technology is a novel antibody test designed for the detection of Mycoplasma antibodies, representing a significant advancement in Mycoplasma detection methods. This test offers a rapid and reliable means of diagnosing Mycoplasma infections, which is particularly valuable in research and clinical settings. Unlike existing tests, this innovative approach provides specificity and sensitivity in detecting Mycoplasma antibodies, ensuring accurate and timely diagnosis. The technology's development stage is currently at the prototype phase, indicating that it is undergoing initial testing and refinement to optimize its performance. Once fully developed, this antibody test has the potential to revolutionize Mycoplasma detection, improving research outcomes and patient care.

# data[].attributes.field_commercial_applications.value
The novel antibody test for Mycoplasma detection has a wide range of potential applications across various fields. In research settings, it can be used to screen cell cultures for Mycoplasma contamination, ensuring the integrity of experiments and the reliability of research outcomes. In clinical settings, the test can aid in the diagnosis of Mycoplasma infections, enabling healthcare providers to administer appropriate treatments promptly. Additionally, the test may find applications in veterinary medicine, agriculture, and environmental monitoring, where Mycoplasma contamination can have significant impacts. The test's versatility and reliability make it a valuable tool for a diverse range of applications, highlighting its potential to address key challenges in multiple industries.

# data[].attributes.field_commercial_applications.processed
The novel antibody test for Mycoplasma detection has a wide range of potential applications across various fields. In research settings, it can be used to screen cell cultures for Mycoplasma contamination, ensuring the integrity of experiments and the reliability of research outcomes. In clinical settings, the test can aid in the diagnosis of Mycoplasma infections, enabling healthcare providers to administer appropriate treatments promptly. Additionally, the test may find applications in veterinary medicine, agriculture, and environmental monitoring, where Mycoplasma contamination can have significant impacts. The test's versatility and reliability make it a valuable tool for a diverse range of applications, highlighting its potential to address key challenges in multiple industries.

# data[].attributes.field_competitive_advantages.value
This novel antibody test for Mycoplasma detection offers several competitive advantages over existing methods. Firstly, it is the first of its kind, providing a unique solution to a previously unmet need in the field. Its specificity and sensitivity in detecting Mycoplasma antibodies surpass current standards, ensuring accurate and reliable results. Additionally, the test is designed to be rapid and easy to use, saving time and resources compared to traditional methods. Its innovative approach has the potential to significantly improve research and clinical outcomes related to Mycoplasma infections. As the technology advances towards commercialization, these competitive advantages position it as a game-changer in the field of Mycoplasma detection and diagnosis.

# data[].attributes.field_competitive_advantages.processed
This novel antibody test for Mycoplasma detection offers several competitive advantages over existing methods. Firstly, it is the first of its kind, providing a unique solution to a previously unmet need in the field. Its specificity and sensitivity in detecting Mycoplasma antibodies surpass current standards, ensuring accurate and reliable results. Additionally, the test is designed to be rapid and easy to use, saving time and resources compared to traditional methods. Its innovative approach has the potential to significantly improve research and clinical outcomes related to Mycoplasma infections. As the technology advances towards commercialization, these competitive advantages position it as a game-changer in the field of Mycoplasma detection and diagnosis.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection.

# data[].attributes.title
A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics

# data[].attributes.body.value
BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome sequences into cDNA plasmids under a T7 RNA polymerase promoter, BSR T7/5 cells facilitate the transcription of RNA antigenomes and mRNA encoding RNP elements, leading to the assembly of infectious viruses. Notably, this system does not require helper viruses, and the cell line's permissiveness, attributed to the absence of a functional type 1 interferon response, makes it especially valuable for viruses replicating in the cytoplasm.

# data[].attributes.body.processed
BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome sequences into cDNA plasmids under a T7 RNA polymerase promoter, BSR T7/5 cells facilitate the transcription of RNA antigenomes and mRNA encoding RNP elements, leading to the assembly of infectious viruses. Notably, this system does not require helper viruses, and the cell line's permissiveness, attributed to the absence of a functional type 1 interferon response, makes it especially valuable for viruses replicating in the cytoplasm.

# data[].attributes.field_commercial_applications.value
The applications of BSR T7/5 cells extend across various fields, offering immense potential in virology, vaccine development, and antiviral drug discovery. Their ability to efficiently recover RNA viruses through reverse genetics makes them invaluable for studying viral pathogenesis, host-virus interactions, and viral evolution. In vaccine development, these cells can be instrumental in generating attenuated or modified viruses for vaccine candidates, particularly for viruses that replicate in the cytoplasm. Furthermore, BSR T7/5 cells hold promise in antiviral drug screening, allowing researchers to evaluate the efficacy of antiviral compounds against a wide range of RNA viruses. Overall, the versatility and reliability of BSR T7/5 cells make them a key tool for advancing our understanding of RNA viruses and developing strategies to combat them.

# data[].attributes.field_commercial_applications.processed
The applications of BSR T7/5 cells extend across various fields, offering immense potential in virology, vaccine development, and antiviral drug discovery. Their ability to efficiently recover RNA viruses through reverse genetics makes them invaluable for studying viral pathogenesis, host-virus interactions, and viral evolution. In vaccine development, these cells can be instrumental in generating attenuated or modified viruses for vaccine candidates, particularly for viruses that replicate in the cytoplasm. Furthermore, BSR T7/5 cells hold promise in antiviral drug screening, allowing researchers to evaluate the efficacy of antiviral compounds against a wide range of RNA viruses. Overall, the versatility and reliability of BSR T7/5 cells make them a key tool for advancing our understanding of RNA viruses and developing strategies to combat them.

# data[].attributes.field_competitive_advantages.value
BSR T7/5 cells offer distinct competitive advantages over traditional methods for RNA virus recovery. Their efficiency in recovering RNA viruses from cDNA plasmids via reverse genetics surpasses that of other cell lines, particularly for members of the mononegavirales order. Unlike many existing approaches, the use of BSR T7/5 cells does not necessitate the presence of helper viruses, streamlining the recovery process. Additionally, the cell line's high permissiveness to RNA viruses, attributed to its lack of a functional type 1 interferon response, enhances the range of viruses that can be studied and recovered. These advantages make BSR T7/5 cells a superior choice for researchers seeking a reliable, efficient, and versatile platform for RNA virus recovery and study.

# data[].attributes.field_competitive_advantages.processed
BSR T7/5 cells offer distinct competitive advantages over traditional methods for RNA virus recovery. Their efficiency in recovering RNA viruses from cDNA plasmids via reverse genetics surpasses that of other cell lines, particularly for members of the mononegavirales order. Unlike many existing approaches, the use of BSR T7/5 cells does not necessitate the presence of helper viruses, streamlining the recovery process. Additionally, the cell line's high permissiveness to RNA viruses, attributed to its lack of a functional type 1 interferon response, enhances the range of viruses that can be studied and recovered. These advantages make BSR T7/5 cells a superior choice for researchers seeking a reliable, efficient, and versatile platform for RNA virus recovery and study.

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics.

# data[].attributes.field_technology_names[]
BSR T7/5 Cells: Baby Hamster Kidney (BHK-21) Cells Stably Expressing Phage T7 RNA Polymerase

# data[].attributes.body.value
This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines. The production of these mAbs involves genetic engineering of mammalian cell lines, enabling their consistent and efficient production. While the in vitro results are promising, rigorous in vivo animal protection assays are necessary to confirm their effectiveness in providing protection against rabies, ultimately offering a promising solution to a disease that remains almost invariably fatal once clinical symptoms develop.

# data[].attributes.body.processed
This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines. The production of these mAbs involves genetic engineering of mammalian cell lines, enabling their consistent and efficient production. While the in vitro results are promising, rigorous in vivo animal protection assays are necessary to confirm their effectiveness in providing protection against rabies, ultimately offering a promising solution to a disease that remains almost invariably fatal once clinical symptoms develop.

# data[].attributes.field_commercial_applications.value
These highly potent rabies-neutralizing monoclonal antibodies (mAbs) have diverse potential applications. They can enhance postexposure prophylaxis (PEP), improving survival rates for rabies-exposed individuals. Their utility extends to research, aiding in the study of rabies and the development of new treatments. With scalability and production efficiency, they are accessible tools for rabies control in regions facing shortages or high incidence rates, offering versatile solutions in the fight against rabies.

# data[].attributes.field_commercial_applications.processed
These highly potent rabies-neutralizing monoclonal antibodies (mAbs) have diverse potential applications. They can enhance postexposure prophylaxis (PEP), improving survival rates for rabies-exposed individuals. Their utility extends to research, aiding in the study of rabies and the development of new treatments. With scalability and production efficiency, they are accessible tools for rabies control in regions facing shortages or high incidence rates, offering versatile solutions in the fight against rabies.

# data[].attributes.field_competitive_advantages.value
This technology's competitive advantages stem from its development of highly potent monoclonal antibodies (mAbs) for rabies prevention. These mAbs, such as F2 and G5a, offer superior protection compared to existing options. Additionally, their production through genetically engineered cell lines ensures a reliable supply, potentially addressing the global shortage of rabies immunoglobulin (RIG). By enhancing postexposure prophylaxis (PEP) when combined with rabies vaccines, this technology improves effectiveness and accessibility in regions with a high rabies incidence, making it a competitive solution in the fight against this deadly disease.

# data[].attributes.field_competitive_advantages.processed
This technology's competitive advantages stem from its development of highly potent monoclonal antibodies (mAbs) for rabies prevention. These mAbs, such as F2 and G5a, offer superior protection compared to existing options. Additionally, their production through genetically engineered cell lines ensures a reliable supply, potentially addressing the global shortage of rabies immunoglobulin (RIG). By enhancing postexposure prophylaxis (PEP) when combined with rabies vaccines, this technology improves effectiveness and accessibility in regions with a high rabies incidence, making it a competitive solution in the fight against this deadly disease.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_technology_names[]
Development Of Chimpanzee/Human Neutralizing Monoclonal  Antibodies Against Rabies

# data[].attributes.title
TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights

# data[].attributes.body.value
This technology involves studying the role of the Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) gene in Hepatitis C Virus (HCV) infection and hepatocellular carcinoma. Researchers perform transcriptomics analysis on liver specimens from HCV-infected patients, identify TACSTD2 as a key gene, and create a stable cell line that overexpresses TACSTD2 to investigate its impact on HCV infection and replication. This technology aims to provide insights into the molecular mechanisms of HCV infection and its association with liver cancer.

# data[].attributes.body.processed
This technology involves studying the role of the Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) gene in Hepatitis C Virus (HCV) infection and hepatocellular carcinoma. Researchers perform transcriptomics analysis on liver specimens from HCV-infected patients, identify TACSTD2 as a key gene, and create a stable cell line that overexpresses TACSTD2 to investigate its impact on HCV infection and replication. This technology aims to provide insights into the molecular mechanisms of HCV infection and its association with liver cancer.

# data[].attributes.field_commercial_applications.value
This technology has versatile potential applications. It can enhance our understanding of HCV infection mechanisms, leading to new treatments for HCV-related liver diseases. Additionally, the TACSTD2-overexpressing cell line offers opportunities for broader molecular studies. Its transcriptomics approach may also inspire similar investigations in other viral infections, advancing our knowledge of infectious diseases and aiding in treatment development.

# data[].attributes.field_commercial_applications.processed
This technology has versatile potential applications. It can enhance our understanding of HCV infection mechanisms, leading to new treatments for HCV-related liver diseases. Additionally, the TACSTD2-overexpressing cell line offers opportunities for broader molecular studies. Its transcriptomics approach may also inspire similar investigations in other viral infections, advancing our knowledge of infectious diseases and aiding in treatment development.

# data[].attributes.field_competitive_advantages.value
This technology's competitive advantages stem from its focused approach on the TACSTD2 gene, leveraging cutting-edge transcriptomics analysis to identify differentially expressed genes in HCV-infected patients, and establishing a stable cell line overexpressing TACSTD2 for precise experiments. With a direct link to HCV-associated hepatocellular carcinoma, it offers clinical relevance and the potential for therapeutic insights. Its applicability extends beyond HCV research, making it a versatile tool for various biomedical investigations, ultimately contributing to advancements in understanding HCV infection and its implications in liver diseases.

# data[].attributes.field_competitive_advantages.processed
This technology's competitive advantages stem from its focused approach on the TACSTD2 gene, leveraging cutting-edge transcriptomics analysis to identify differentially expressed genes in HCV-infected patients, and establishing a stable cell line overexpressing TACSTD2 for precise experiments. With a direct link to HCV-associated hepatocellular carcinoma, it offers clinical relevance and the potential for therapeutic insights. Its applicability extends beyond HCV research, making it a versatile tool for various biomedical investigations, ultimately contributing to advancements in understanding HCV infection and its implications in liver diseases.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights&body=Please send me information about technology [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights&body=Please send me information about technology [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights.

# data[].attributes.field_technology_names[]
Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-overexpressing Huh7.5 Cells

# data[].attributes.title
Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients

# data[].attributes.body.value
The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), making it a promising tool for identifying anti-VZV antibodies in individuals who have received the VZV vaccine. However, potential patent challenges may arise due to similarities with assays used for related herpesviruses, and the market for this technology is relatively niche, primarily targeting populations at higher risk of VZV infection, such as pregnant women and healthcare workers.

# data[].attributes.body.processed
The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), making it a promising tool for identifying anti-VZV antibodies in individuals who have received the VZV vaccine. However, potential patent challenges may arise due to similarities with assays used for related herpesviruses, and the market for this technology is relatively niche, primarily targeting populations at higher risk of VZV infection, such as pregnant women and healthcare workers.

# data[].attributes.field_commercial_applications.value
The high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection has versatile potential applications. It can be used for vaccine studies, epidemiological research, and clinical diagnostics, offering accurate results similar to the FAMA test. Despite potential patent challenges, it's well-suited for specialized purposes like assessing vaccine responses in pregnant women and screening high-risk healthcare workers. This makes it valuable in focused serological research and diagnostics.

# data[].attributes.field_commercial_applications.processed
The high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection has versatile potential applications. It can be used for vaccine studies, epidemiological research, and clinical diagnostics, offering accurate results similar to the FAMA test. Despite potential patent challenges, it's well-suited for specialized purposes like assessing vaccine responses in pregnant women and screening high-risk healthcare workers. This makes it valuable in focused serological research and diagnostics.

# data[].attributes.field_competitive_advantages.value
The proposed high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection offers key competitive advantages. It provides quantitative results, enables efficient screening of numerous samples, and matches the sensitivity of the established FAMA test. While patent challenges may arise, this technology serves niche markets, like pregnant women and healthcare workers at higher risk of VZV exposure, making it a valuable tool for focused serological diagnosis and research.

# data[].attributes.field_competitive_advantages.processed
The proposed high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection offers key competitive advantages. It provides quantitative results, enables efficient screening of numerous samples, and matches the sensitivity of the established FAMA test. While patent challenges may arise, this technology serves niche markets, like pregnant women and healthcare workers at higher risk of VZV exposure, making it a valuable tool for focused serological diagnosis and research.

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients.

# data[].attributes.field_technology_names[]
Luciferase Immunoprecipitation Systems Assay To Detect Antibody To Varicella-Zoster Virus In Varicella Vaccine Recipients

# data[].attributes.title
Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2

# data[].attributes.body.value
In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP expression can be easily detected through fluorescence microscopy in live or fixed cells, providing a sensitive tool for both research and drug discovery. Importantly, placing GFP in the first-gene position minimizes interference with the expression of key RSV interferon antagonist genes, maintaining the virus's functionality while enhancing the brightness and utility of the GFP marker. This technology offers valuable insights into RSV infection dynamics and facilitates high-throughput screening for potential therapeutic agents.

# data[].attributes.body.processed
In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP expression can be easily detected through fluorescence microscopy in live or fixed cells, providing a sensitive tool for both research and drug discovery. Importantly, placing GFP in the first-gene position minimizes interference with the expression of key RSV interferon antagonist genes, maintaining the virus's functionality while enhancing the brightness and utility of the GFP marker. This technology offers valuable insights into RSV infection dynamics and facilitates high-throughput screening for potential therapeutic agents.

# data[].attributes.field_commercial_applications.value
This technology has versatile potential applications. It aids in better understanding RSV infection, enabling high-throughput screening for antiviral compounds and vaccine development. Additionally, it has broader applications in respiratory virus research, offering insights into host interactions and potential treatments for various viral infections.

# data[].attributes.field_commercial_applications.processed
This technology has versatile potential applications. It aids in better understanding RSV infection, enabling high-throughput screening for antiviral compounds and vaccine development. Additionally, it has broader applications in respiratory virus research, offering insights into host interactions and potential treatments for various viral infections.

# data[].attributes.field_competitive_advantages.value
The incorporation of green fluorescent protein (GFP) into the first-gene position of Respiratory Syncytial Virus (RSV) strain A2 offers a competitive advantage by providing a highly sensitive and non-invasive method for monitoring RSV infection. This modification ensures a robust and bright signal for accurate tracking, while strategically minimizing interference with key RSV genes. Researchers can better study the virus and expedite drug discovery efforts with this enhanced technology.

# data[].attributes.field_competitive_advantages.processed
The incorporation of green fluorescent protein (GFP) into the first-gene position of Respiratory Syncytial Virus (RSV) strain A2 offers a competitive advantage by providing a highly sensitive and non-invasive method for monitoring RSV infection. This modification ensures a robust and bright signal for accurate tracking, while strategically minimizing interference with key RSV genes. Researchers can better study the virus and expedite drug discovery efforts with this enhanced technology.

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2.

# data[].attributes.field_technology_names[]
Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) From An Added Gene In The Fifth-gene Position

# data[].attributes.title
Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening

# data[].attributes.body.value
The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers can use it to study HMPV behavior in real-time, identify potential antiviral compounds, and quantify viral particles in samples, making it invaluable for advancing our understanding of HMPV infections and the development of antiviral interventions.

# data[].attributes.body.processed
The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers can use it to study HMPV behavior in real-time, identify potential antiviral compounds, and quantify viral particles in samples, making it invaluable for advancing our understanding of HMPV infections and the development of antiviral interventions.

# data[].attributes.field_commercial_applications.value
Incorporating enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers versatile applications, including virology research for infection mechanisms, high-throughput drug screening, sensitive diagnostics, and vaccine development.

# data[].attributes.field_commercial_applications.processed
Incorporating enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers versatile applications, including virology research for infection mechanisms, high-throughput drug screening, sensitive diagnostics, and vaccine development.

# data[].attributes.field_competitive_advantages.value
The incorporation of enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers a competitive advantage by providing a precise and rapid method for monitoring virus infection. This technology enables real-time visualization, simplifies high-throughput screening for potential antiviral agents, and streamlines viral particle quantification through GFP-based assays. Its sensitivity and efficiency make it a valuable tool for advancing virology research and expediting antiviral drug discovery.

# data[].attributes.field_competitive_advantages.processed
The incorporation of enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers a competitive advantage by providing a precise and rapid method for monitoring virus infection. This technology enables real-time visualization, simplifies high-throughput screening for potential antiviral agents, and streamlines viral particle quantification through GFP-based assays. Its sensitivity and efficiency make it a valuable tool for advancing virology research and expediting antiviral drug discovery.

# data[].attributes.field_inventor_companies[]
Institut national de la recherche agronomique (INRA)

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening.

# data[].attributes.field_technology_names[]
Human Metapneumovirus (HMPV) Expressing Green Fluorescent Protein (GFP) At The First Position (HMPV-GFP1) From An Added Gene

# data[].attributes.title
Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes

# data[].attributes.body.value
The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays. The engineered RSV strain also contains a mutation in the RSV G protein, making it a valuable tool for high-throughput screening of potential antiviral compounds. This technology offers a sensitive and efficient method for studying RSV infection and screening for inhibitors, facilitating both basic research and drug development efforts related to RSV.

# data[].attributes.body.processed
The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays. The engineered RSV strain also contains a mutation in the RSV G protein, making it a valuable tool for high-throughput screening of potential antiviral compounds. This technology offers a sensitive and efficient method for studying RSV infection and screening for inhibitors, facilitating both basic research and drug development efforts related to RSV.

# data[].attributes.field_commercial_applications.value
This technology has diverse potential applications in RSV research and antiviral drug development. It enables rapid screening of antiviral compounds, facilitates the study of RSV infection dynamics, and aids in evaluating vaccines and therapies. The GFP and luciferase markers offer real-time monitoring for investigating RSV replication and pathogenesis. Overall, this versatile technology enhances our understanding of RSV and accelerates efforts to combat this respiratory virus.

# data[].attributes.field_commercial_applications.processed
This technology has diverse potential applications in RSV research and antiviral drug development. It enables rapid screening of antiviral compounds, facilitates the study of RSV infection dynamics, and aids in evaluating vaccines and therapies. The GFP and luciferase markers offer real-time monitoring for investigating RSV replication and pathogenesis. Overall, this versatile technology enhances our understanding of RSV and accelerates efforts to combat this respiratory virus.

# data[].attributes.field_competitive_advantages.value
This technology offers a competitive edge by enabling real-time monitoring of RSV infection through the use of GFP and Renilla luciferase markers, allowing for precise and sensitive assessments of viral replication. The engineered RSV strain's safety features, such as a mutated RSV G protein, enhance laboratory safety. These advantages streamline RSV research and drug development efforts, making it a powerful tool for studying the virus and screening potential inhibitors.

# data[].attributes.field_competitive_advantages.processed
This technology offers a competitive edge by enabling real-time monitoring of RSV infection through the use of GFP and Renilla luciferase markers, allowing for precise and sensitive assessments of viral replication. The engineered RSV strain's safety features, such as a mutated RSV G protein, enhance laboratory safety. These advantages streamline RSV research and drug development efforts, making it a powerful tool for studying the virus and screening potential inhibitors.

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes.

# data[].attributes.field_technology_names[]
Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) And Luciferase From Added Genes

# data[].attributes.title
Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery

# data[].attributes.body.value
This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments. Its effectiveness is underscored by a study involving 865 neurological exams, where the app's computed scales matched the accuracy of multiple sclerosis-trained clinicians. Crucially, NeurEx® enhances the sensitivity and specificity in tracking disability progression, outperforming traditional scales like the EDSS. This makes it an invaluable asset not only in clinical settings but also in research and multicentric trials, offering a more economical and precise alternative to conventional documentation of neurological examinations.

# data[].attributes.body.processed
This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments. Its effectiveness is underscored by a study involving 865 neurological exams, where the app's computed scales matched the accuracy of multiple sclerosis-trained clinicians. Crucially, NeurEx® enhances the sensitivity and specificity in tracking disability progression, outperforming traditional scales like the EDSS. This makes it an invaluable asset not only in clinical settings but also in research and multicentric trials, offering a more economical and precise alternative to conventional documentation of neurological examinations.

# data[].attributes.field_commercial_applications.value
The technology holds promise for facilitating detailed structural studies of the RSV replication mechanism, advancing antiviral drug development, and potentially applying similar methods to other significant negative-sense RNA viruses like measles and ebola.

# data[].attributes.field_commercial_applications.processed
The technology holds promise for facilitating detailed structural studies of the RSV replication mechanism, advancing antiviral drug development, and potentially applying similar methods to other significant negative-sense RNA viruses like measles and ebola.

# data[].attributes.field_competitive_advantages.value
This technology uniquely enables the high-yield production and purification of the RSV replication complex in human cells, paving the way for groundbreaking antiviral drug discovery and structural analysis of the virus.

# data[].attributes.field_competitive_advantages.processed
This technology uniquely enables the high-yield production and purification of the RSV replication complex in human cells, paving the way for groundbreaking antiviral drug discovery and structural analysis of the virus.

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery.

# data[].attributes.field_technology_names[]
Generation Of A Human Cell Line That Constitutively Expresses Respiratory Syncytial Virus (RSV) Nucleocapsid (N), Phosphoprotein
(P) And Polymerase (L) Proteins, And Purification Of The RSV Replication Complex

# data[].attributes.title
Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development

# data[].attributes.body.value
The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV. Prepared using standard cell culture methods, these S10-3 cells from the Huh-7 line demonstrated superior abilities in both transfectability and infectivity, making them highly valuable for virological research focused on Hepatitis E Virus.

# data[].attributes.body.processed
The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV. Prepared using standard cell culture methods, these S10-3 cells from the Huh-7 line demonstrated superior abilities in both transfectability and infectivity, making them highly valuable for virological research focused on Hepatitis E Virus.

# data[].attributes.field_commercial_applications.value
The S10-3 cell line, with its heightened transfection and infection capabilities, holds potential for groundbreaking advances in the study and development of treatments and vaccines for Hepatitis E Virus.

# data[].attributes.field_commercial_applications.processed
The S10-3 cell line, with its heightened transfection and infection capabilities, holds potential for groundbreaking advances in the study and development of treatments and vaccines for Hepatitis E Virus.

# data[].attributes.field_competitive_advantages.value
The S10-3 cells, derived from the Huh-7 cell line, offer a significant competitive advantage in Hepatitis E Virus research due to their enhanced efficiency in transfection and infection processes.

# data[].attributes.field_competitive_advantages.processed
The S10-3 cells, derived from the Huh-7 cell line, offer a significant competitive advantage in Hepatitis E Virus research due to their enhanced efficiency in transfection and infection processes.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development.

# data[].attributes.field_publications[].value
Emerson, S.

# data[].attributes.field_publications[].processed
Emerson, S.

# data[].attributes.field_technology_names[]
Huh-7 Cell Line Derived S10-3 Cells For Hepatitis E Virus Infection Studies

# data[].attributes.title
Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line

# data[].attributes.body.value
Worldwide, 130-150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the global disease burden is hampered by remarkably high treatment costs and a high number of undiagnosed infections. Moreover, a significant number of patients develop resistance and additional treatment modalities may be needed to dramatically reduce the worldwide incidence of HCV infection. The subject cell line may be a useful tool for studying the mechanism of HCV cellular entry and replication and could be incorporated into an in vitro assay to measure the effectiveness of novel HCV targeted therapies or as a system for improved propagation of HCV in culture.

By overexpressing TACSTD2 in Huh7.5 cells, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) discovered that they could restore the cellular localization of two host cell HCV-entry factors that become dysregulated in hepatocellular carcinoma (HCC) cells. Overexpression of TACSTD2 makes Huh7.5 cells more broadly permissive to infection and replication by multiple HCV genotypes in comparison to the canonical Huh7.5 cell model. HCV does not replicate in malignant HCC cells, possibly caused in part by downregulation of TACSTD2 expression.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

# data[].attributes.body.processed
Worldwide, 130-150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the global disease burden is hampered by remarkably high treatment costs and a high number of undiagnosed infections. Moreover, a significant number of patients develop resistance and additional treatment modalities may be needed to dramatically reduce the worldwide incidence of HCV infection. The subject cell line may be a useful tool for studying the mechanism of HCV cellular entry and replication and could be incorporated into an in vitro assay to measure the effectiveness of novel HCV targeted therapies or as a system for improved propagation of HCV in culture.

By overexpressing TACSTD2 in Huh7.5 cells, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) discovered that they could restore the cellular localization of two host cell HCV-entry factors that become dysregulated in hepatocellular carcinoma (HCC) cells. Overexpression of TACSTD2 makes Huh7.5 cells more broadly permissive to infection and replication by multiple HCV genotypes in comparison to the canonical Huh7.5 cell model. HCV does not replicate in malignant HCC cells, possibly caused in part by downregulation of TACSTD2 expression.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

# data[].attributes.field_collaboration_description.value
Elizabeth Pitts, Ph.D., 240-669-5299; elizabeth.pitts@nih.gov. Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

# data[].attributes.field_collaboration_description.processed
Elizabeth Pitts, Ph.D., 240-669-5299; elizabeth.pitts@nih.gov. Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

# data[].attributes.field_commercial_applications.value
Cell line to study hepatitis C virus infection and replication or propagate HCV in culture.

Cell line to study cancer.

# data[].attributes.field_commercial_applications.processed
Cell line to study hepatitis C virus infection and replication or propagate HCV in culture.

Cell line to study cancer.

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line&body=Please send me information about technology [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line&body=Please send me information about technology [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line.

# data[].attributes.field_technology_names[]
Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-overexpressing Huh7.5 Cells

# data[].attributes.title
Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses

# data[].attributes.body.value
There is a great need for broadly protective, “universal” influenza virus vaccines given the antigenic drift and shift of influenza viruses and the variable protective efficacy of the current influenza vaccines. This technology relates to a broadly protective, “universal” influenza vaccine candidate composed of a cocktail of different low pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL). Vaccinating animals with BPL-inactivated whole virus vaccine comprising influenza virus strains belonging to four or more different low pathogenicity avian influenza hemagglutinin subtypes, intranasally or intramuscularly, provided extremely broad protection and heterosubtypic protection to lethal challenge with influenza viruses in both mice and ferrets. This influenza vaccine technology has a great potential to offer broad protection against both seasonal and pandemic-potential influenza viruses.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.

# data[].attributes.body.processed
There is a great need for broadly protective, “universal” influenza virus vaccines given the antigenic drift and shift of influenza viruses and the variable protective efficacy of the current influenza vaccines. This technology relates to a broadly protective, “universal” influenza vaccine candidate composed of a cocktail of different low pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL). Vaccinating animals with BPL-inactivated whole virus vaccine comprising influenza virus strains belonging to four or more different low pathogenicity avian influenza hemagglutinin subtypes, intranasally or intramuscularly, provided extremely broad protection and heterosubtypic protection to lethal challenge with influenza viruses in both mice and ferrets. This influenza vaccine technology has a great potential to offer broad protection against both seasonal and pandemic-potential influenza viruses.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have the capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at elizabeth.pitts@nih.gov or 240-669-5299.
.
.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have the capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at elizabeth.pitts@nih.gov or 240-669-5299.
.
.

# data[].attributes.field_commercial_applications.value
Vaccine against viruses

Vaccines against influenza virus

Universal influenza virus vaccine

# data[].attributes.field_commercial_applications.processed
Vaccine against viruses

Vaccines against influenza virus

Universal influenza virus vaccine

# data[].attributes.field_competitive_advantages.value
Broad protection to both seasonal and pandemic-potential influenza viruses

Easy and cost-effective inactivation method

Effective immune response due to the use of authentic viral antigens

Animal data available

# data[].attributes.field_competitive_advantages.processed
Broad protection to both seasonal and pandemic-potential influenza viruses

Easy and cost-effective inactivation method

Effective immune response due to the use of authentic viral antigens

Animal data available

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses&body=Please send me information about technology [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses&body=Please send me information about technology [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/620,051
Filed on 2018-01-22
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/620,051
Filed on 2018-01-22
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2019/014220
Filed on 2019-01-18
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2019/014220
Filed on 2019-01-18
Status: Expired

# data[].attributes.field_patents[].value
US Patent 11,369,675
Filed on 2020-07-21
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 11,369,675
Filed on 2020-07-21
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/620,051
Filed on 2018-01-22
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2019/014220
Filed on 2019-01-18
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 11,369,675
Filed on 2020-07-21
Status: Issued

# data[].attributes.field_patent_titles[]
BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE

# data[].attributes.field_patent_titles[]
Development Of A Broadly Protective Influenza Vaccine Consisting Of A Cocktail Of Inactivated Avian Influenza Viruses 1

# data[].attributes.field_patent_titles[]
BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE

# data[].attributes.field_technology_names[]
Development Of A Broadly Protective Influenza Vaccine Consisting Of A Cocktail Of Inactivated Avian Influenza Viruses 1

# data[].attributes.title
Recombinant Respiratory Syncytial Virus Challenge Strain

# data[].attributes.body.value
RSV is the most important viral agent of severe respiratory tract disease worldwide, especially in infants and young children, and it also causes severe disease in the elderly and in immunocompromised individuals. There are no licensed vaccines or antivirals suitable for routine use.

This invention relates to a reverse genetics system and cDNA-derived virus for a contemporary wild-type clinical isolate of RSV of antigenic subgroup A, termed RSV strain A/Maryland/001/11, that was isolated in 2011 from an adult with respiratory illness. The genomic sequence was determined. A reverse genetics system was created encoding a recombinant, replication competent RSV that contains a codon-optimized G ORF, which was done to stabilize the cDNA for replication in bacteria. Because this virus was generated by reverse genetics, it is a “clean” virus with a well-defined passage history. Clinical study material of this challenge virus has been manufactured and is available for use as an U.S. Food and Drug Administration (FDA) regulated Investigational New Drug (IND) in clinical studies in adult volunteers within and outside of the United States. Preliminary clinical data confirmed that this virus efficiently infects and replicates in 95% of study participants pre-selected for pre-existing RSV antibody titers in the bottom 50% of the range. The challenge virus causes mild upper respiratory illness in the majority of infected participants, typical for RSV illness in otherwise healthy adults. This provides a suitable challenge system for evaluating antivirals, as well as vaccines for older children and adults. This also could be used for developing live-attenuated RSV vaccine candidates based on this contemporary strain, using the stabilized point mutations, stabilized codon-deletions, and gene-deletions that were previously used in RSV strain A2.

This invention relates to a reverse genetics system and the encoded RSV vaccine challenge strain that infects and causes disease in RSV-experienced adults and is available for antiviral and vaccine research.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
RSV is the most important viral agent of severe respiratory tract disease worldwide, especially in infants and young children, and it also causes severe disease in the elderly and in immunocompromised individuals. There are no licensed vaccines or antivirals suitable for routine use.

This invention relates to a reverse genetics system and cDNA-derived virus for a contemporary wild-type clinical isolate of RSV of antigenic subgroup A, termed RSV strain A/Maryland/001/11, that was isolated in 2011 from an adult with respiratory illness. The genomic sequence was determined. A reverse genetics system was created encoding a recombinant, replication competent RSV that contains a codon-optimized G ORF, which was done to stabilize the cDNA for replication in bacteria. Because this virus was generated by reverse genetics, it is a “clean” virus with a well-defined passage history. Clinical study material of this challenge virus has been manufactured and is available for use as an U.S. Food and Drug Administration (FDA) regulated Investigational New Drug (IND) in clinical studies in adult volunteers within and outside of the United States. Preliminary clinical data confirmed that this virus efficiently infects and replicates in 95% of study participants pre-selected for pre-existing RSV antibody titers in the bottom 50% of the range. The challenge virus causes mild upper respiratory illness in the majority of infected participants, typical for RSV illness in otherwise healthy adults. This provides a suitable challenge system for evaluating antivirals, as well as vaccines for older children and adults. This also could be used for developing live-attenuated RSV vaccine candidates based on this contemporary strain, using the stabilized point mutations, stabilized codon-deletions, and gene-deletions that were previously used in RSV strain A2.

This invention relates to a reverse genetics system and the encoded RSV vaccine challenge strain that infects and causes disease in RSV-experienced adults and is available for antiviral and vaccine research.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_commercial_applications.value
Vaccine development

Viral diagnostics

Vaccine research

# data[].attributes.field_commercial_applications.processed
Vaccine development

Viral diagnostics

Vaccine research

# data[].attributes.field_competitive_advantages.value
Ease of manufacture

Clinical trial material

Low-cost vaccines

Intranasal administration/needle-free delivery

# data[].attributes.field_competitive_advantages.processed
Ease of manufacture

Clinical trial material

Low-cost vaccines

Intranasal administration/needle-free delivery

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain&body=Please send me information about technology [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain&body=Please send me information about technology [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain.

# data[].attributes.field_technology_names[]
Recombinant Wild-type Respiratory Syncytial Virus RRSV A/Maryland/001/11

# data[].attributes.title
Hybridoma cell lines producing antibodies to RSV NS1

# data[].attributes.body.value
This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist. These antibodies and cell lines may be of interest to any persons investigating RSV infection processes, particularly as it relates to the activity of NS1 in such an infection process.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist. These antibodies and cell lines may be of interest to any persons investigating RSV infection processes, particularly as it relates to the activity of NS1 in such an infection process.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_commercial_applications.value
Viral diagnostics

Vaccine research

# data[].attributes.field_commercial_applications.processed
Viral diagnostics

Vaccine research

# data[].attributes.field_competitive_advantages.value
Ease of manufacture

Unique research tool

# data[].attributes.field_competitive_advantages.processed
Ease of manufacture

Unique research tool

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1&body=Please send me information about technology [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1&body=Please send me information about technology [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1.

# data[].attributes.field_technology_names[]
Hybridoma Cell Lines Producing Antibodies To RSV NS1 And The Imonoclonal Antibodies Against RSV NS1

# data[].attributes.title
Recombinant RSV B1 expressing eGFP as a reporter gene

# data[].attributes.body.value
The inventors have created a reverse genetics system for RSV strain B1 of antigenic subgroup B encoding a replication-competent recombinant RSV that contains a codon-optimized G ORF and expresses enhanced green fluorescence protein (GFP). There are two antigenic subgroups of RSV, subgroups A and B, and most of the available information and reagents are for subgroup A. Immunity against either subgroup has reduced effectiveness in restricting the heterologous subgroup, suggesting that an effective RSV vaccine might need to contain both subgroups. The sequence of the wild type G gene was refractory to cloning into full-length antigenomic cDNA in E. coli, and so the inventors made and successfully used a codon optimized version. In addition, the inventors inserted an eGFP gene into the first gene position (promoter proximal). The resulting virus is replication-competent and efficiently expresses GFP in infected cells. This virus can be used as a tool to detect RSV-neutralizing antibodies to RSV subgroup B in a plaque-reduction assay. It also can be used to evaluate RSV infection in vitro and in vivo using GFP fluorescence to track infection. The antigenomic cDNA clone also provides the starting material for making live-attenuated subgroup B-specific RSV vaccine candidates containing defined mutations. These defined mutations can include ones that we previously developed for RSV subgroup A, and include stabilized point mutations, stabilized codon-deletions, and gene-deletions.

The present invention provides a reverse genetics system encoding strain B1 of RSV subgroup B containing a codon-optimized G ORF and encoding eGFP. This provides a tool for RSV subgroup B serology assays, for tracking RSV infection, and a starting point for making attenuated subgroup B strains for vaccine purposes.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
The inventors have created a reverse genetics system for RSV strain B1 of antigenic subgroup B encoding a replication-competent recombinant RSV that contains a codon-optimized G ORF and expresses enhanced green fluorescence protein (GFP). There are two antigenic subgroups of RSV, subgroups A and B, and most of the available information and reagents are for subgroup A. Immunity against either subgroup has reduced effectiveness in restricting the heterologous subgroup, suggesting that an effective RSV vaccine might need to contain both subgroups. The sequence of the wild type G gene was refractory to cloning into full-length antigenomic cDNA in E. coli, and so the inventors made and successfully used a codon optimized version. In addition, the inventors inserted an eGFP gene into the first gene position (promoter proximal). The resulting virus is replication-competent and efficiently expresses GFP in infected cells. This virus can be used as a tool to detect RSV-neutralizing antibodies to RSV subgroup B in a plaque-reduction assay. It also can be used to evaluate RSV infection in vitro and in vivo using GFP fluorescence to track infection. The antigenomic cDNA clone also provides the starting material for making live-attenuated subgroup B-specific RSV vaccine candidates containing defined mutations. These defined mutations can include ones that we previously developed for RSV subgroup A, and include stabilized point mutations, stabilized codon-deletions, and gene-deletions.

The present invention provides a reverse genetics system encoding strain B1 of RSV subgroup B containing a codon-optimized G ORF and encoding eGFP. This provides a tool for RSV subgroup B serology assays, for tracking RSV infection, and a starting point for making attenuated subgroup B strains for vaccine purposes.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., please contact Peter Soukas, J.D. at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., please contact Peter Soukas, J.D. at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_commercial_applications.value
Viral diagnostics

Vaccine research

Serology assays

Vaccine manufacture

# data[].attributes.field_commercial_applications.processed
Viral diagnostics

Vaccine research

Serology assays

Vaccine manufacture

# data[].attributes.field_competitive_advantages.value
Ease of manufacture

Unique research tool

# data[].attributes.field_competitive_advantages.processed
Ease of manufacture

Unique research tool

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene&body=Please send me information about technology [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene&body=Please send me information about technology [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene.

# data[].attributes.field_technology_names[]
Recombinant R~V B 1, Expressing EGFP As A Reporter Gene

# data[].attributes.title
Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine

# data[].attributes.body.value
Ebola virus (EBOV) hemorrhagic fever is one of the most lethal viral infections and lacks a licensed vaccine. EBOV is transmitted by contact with body fluids from infected individuals including droplets or aerosols. Aerosolized EBOV could also be exploited for intentional virus spread. Therefore, vaccines that protect against mucosal and systemic exposure are needed.

The NIH/NIAID has developed recombinant human parainfluenza virus type 1 (rHPIV1) bearing a stabilized attenuating mutation in the P/C gene to express the membrane-anchored form of EBOV glycoprotein GP as an intranasal (IN) EBOV vaccine. GP was codon optimized and expressed either as a full-length protein or a chimeric form in which its transmembrane and cytoplasmic tail (TMCT) domains were substituted with those of the HPIV1 F protein in an effort to increase packaging into the vector particle and enhance immunogenicity. GP was inserted either preceding the N gene (pre-N) or between the N and P genes (N-P) of rHPIV1. All vectors replicated to high titers in vitro and had stable GP expression. Viruses were attenuated and replicated at low titers in the respiratory tract of African green monkeys. Two doses of candidates expressing GP from the pre-N position elicited higher GP neutralizing serum antibody titers than the N-P viruses, and unmodified GP induced higher levels than its TMCT counterpart. Unmodified EBOV GP was packaged into the HPIV1 particle, and the TMCT modification did not increase packaging or immunogenicity. Overall, the candidate expressing full-length GP from the Pre-N position was the most immunogenic.

This invention relates to an attenuated and immunogenic IN vaccine candidate expected to be well tolerated in humans and is available for clinical evaluation.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
Ebola virus (EBOV) hemorrhagic fever is one of the most lethal viral infections and lacks a licensed vaccine. EBOV is transmitted by contact with body fluids from infected individuals including droplets or aerosols. Aerosolized EBOV could also be exploited for intentional virus spread. Therefore, vaccines that protect against mucosal and systemic exposure are needed.

The NIH/NIAID has developed recombinant human parainfluenza virus type 1 (rHPIV1) bearing a stabilized attenuating mutation in the P/C gene to express the membrane-anchored form of EBOV glycoprotein GP as an intranasal (IN) EBOV vaccine. GP was codon optimized and expressed either as a full-length protein or a chimeric form in which its transmembrane and cytoplasmic tail (TMCT) domains were substituted with those of the HPIV1 F protein in an effort to increase packaging into the vector particle and enhance immunogenicity. GP was inserted either preceding the N gene (pre-N) or between the N and P genes (N-P) of rHPIV1. All vectors replicated to high titers in vitro and had stable GP expression. Viruses were attenuated and replicated at low titers in the respiratory tract of African green monkeys. Two doses of candidates expressing GP from the pre-N position elicited higher GP neutralizing serum antibody titers than the N-P viruses, and unmodified GP induced higher levels than its TMCT counterpart. Unmodified EBOV GP was packaged into the HPIV1 particle, and the TMCT modification did not increase packaging or immunogenicity. Overall, the candidate expressing full-length GP from the Pre-N position was the most immunogenic.

This invention relates to an attenuated and immunogenic IN vaccine candidate expected to be well tolerated in humans and is available for clinical evaluation.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D. at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D. at Peter.Soukas@nih.gov or 301-594-8730.

# data[].attributes.field_commercial_applications.value
Viral diagnostics

Vaccine research

# data[].attributes.field_commercial_applications.processed
Viral diagnostics

Vaccine research

# data[].attributes.field_competitive_advantages.value
Ease of manufacture

Bivalent or Multivalent live attenuated vaccines

B cell and T cell activation

Low-cost vaccines

Intranasal administration/needle-free delivery

# data[].attributes.field_competitive_advantages.processed
Ease of manufacture

Bivalent or Multivalent live attenuated vaccines

B cell and T cell activation

Low-cost vaccines

Intranasal administration/needle-free delivery

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine&body=Please send me information about technology [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine&body=Please send me information about technology [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine.

# data[].attributes.field_publications[].value
Lingemann M, et al.

# data[].attributes.field_publications[].processed
Lingemann M, et al.

# data[].attributes.field_technology_names[]
Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP As An Intranasal Ebola Vaccine

# data[].attributes.title
Protein Nanoparticles for Antigen Display in Vaccines

# data[].attributes.body.value
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hepatitis B virus core proteins can be disassembled and re-assembled, allowing mixing of antigens. Furthermore, the nanoparticles can be expressed in prokaryotic and eukaryotic expression systems. Thus, the platform provides a means for an optimal display of influenza epitopes for the induction of immune response including broadly neutralizing antibodies against the virus and therefore has the potential to be developed into an efficient universal vaccine against influenza virus infection.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hepatitis B virus core proteins can be disassembled and re-assembled, allowing mixing of antigens. Furthermore, the nanoparticles can be expressed in prokaryotic and eukaryotic expression systems. Thus, the platform provides a means for an optimal display of influenza epitopes for the induction of immune response including broadly neutralizing antibodies against the virus and therefore has the potential to be developed into an efficient universal vaccine against influenza virus infection.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have one or more of the following capabilities: (1) capacity to produce recombinant protein for animal vaccine studies; (2) perform and evaluate immunogenicity (antibody response) of influenza vaccine antigens in animal (e.g. mouse models); (3) perform and evaluate challenge and protection studies of vaccines and influenza viruses. (e.g. mouse models); and (4) if results are promising from animal studies, capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at elizabeth.pitts@nih.gov or 240-669-5299.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have one or more of the following capabilities: (1) capacity to produce recombinant protein for animal vaccine studies; (2) perform and evaluate immunogenicity (antibody response) of influenza vaccine antigens in animal (e.g. mouse models); (3) perform and evaluate challenge and protection studies of vaccines and influenza viruses. (e.g. mouse models); and (4) if results are promising from animal studies, capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at elizabeth.pitts@nih.gov or 240-669-5299.

# data[].attributes.field_commercial_applications.value
Vaccine against viruses; vaccines against influenza virus; universal influenza virus vaccine

# data[].attributes.field_commercial_applications.processed
Vaccine against viruses; vaccines against influenza virus; universal influenza virus vaccine

# data[].attributes.field_competitive_advantages.value
The nanoparticles may be disassembled and re-assembled allowing mixing of antigens

Expression in prokaryotic and eukaryotic systems

Avoids production and usage of live viruses for vaccine generation

Effective immune response due to the use of authentic viral antigens

Stability of particle and immunogenicity after high temperature exposure

Incorporation of epitopes from group 1 and group 2 influenza viruses

Broadly neutralizing antibodies against influenza virus

# data[].attributes.field_competitive_advantages.processed
The nanoparticles may be disassembled and re-assembled allowing mixing of antigens

Expression in prokaryotic and eukaryotic systems

Avoids production and usage of live viruses for vaccine generation

Effective immune response due to the use of authentic viral antigens

Stability of particle and immunogenicity after high temperature exposure

Incorporation of epitopes from group 1 and group 2 influenza viruses

Broadly neutralizing antibodies against influenza virus

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines&body=Please send me information about technology [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines&body=Please send me information about technology [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/540,474
Filed on 2017-08-02
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/540,474
Filed on 2017-08-02
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2018/045032
Filed on 2018-08-02
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2018/045032
Filed on 2018-08-02
Status: Expired

# data[].attributes.field_patents[].value
US Patent 11,535,651
Filed on 2020-01-30
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 11,535,651
Filed on 2020-01-30
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/540,474
Filed on 2017-08-02
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2018/045032
Filed on 2018-08-02
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 11,535,651
Filed on 2020-01-30
Status: Issued

# data[].attributes.field_patent_titles[]
Hepatitis B Nanoparticle-Based Vaccine For Influenza Virus

# data[].attributes.field_patent_titles[]
HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS

# data[].attributes.field_patent_titles[]
HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS

# data[].attributes.field_publications[].value
Dustin M. McCraw, et al.

# data[].attributes.field_publications[].processed
Dustin M. McCraw, et al.

# data[].attributes.field_technology_names[]
Protein Nanoparticles For Antigen Display

# data[].attributes.title
A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development

# data[].attributes.body.value
An arthropod-borne virus, Zika virus (ZIKV), has recently emerged as a major human pathogen.  Associated with complications during perinatal development and Guillain-Barré syndrome in adults, ZIKV raises new challenges for understanding the molecular determinants of flavivirus pathogenesis.  This underscores the necessity for the development of a reverse genetic system based on an epidemic ZIKV strain.  This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil.  The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin.  It was observed that the growth of cDNA-derived virus was attenuated compared to the growth of the parental isolate in most cell lines, which correlates with substantial differences in sequence heterogeneity between these viruses that were determined by deep-sequencing analysis.  Moreover, these results indicate that caution should be exercised when interpreting the results of reverse-genetics experiments in attempts to accurately predict the biology of natural viruses.  Finally, a Vero cell-adapted cDNA clone of ZIKV was generated that can be used as a convenient platform for studies aimed at the development of ZIKV vaccines (live attenuated and inactivated) and therapeutics.

# data[].attributes.body.processed
An arthropod-borne virus, Zika virus (ZIKV), has recently emerged as a major human pathogen.  Associated with complications during perinatal development and Guillain-Barré syndrome in adults, ZIKV raises new challenges for understanding the molecular determinants of flavivirus pathogenesis.  This underscores the necessity for the development of a reverse genetic system based on an epidemic ZIKV strain.  This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil.  The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin.  It was observed that the growth of cDNA-derived virus was attenuated compared to the growth of the parental isolate in most cell lines, which correlates with substantial differences in sequence heterogeneity between these viruses that were determined by deep-sequencing analysis.  Moreover, these results indicate that caution should be exercised when interpreting the results of reverse-genetics experiments in attempts to accurately predict the biology of natural viruses.  Finally, a Vero cell-adapted cDNA clone of ZIKV was generated that can be used as a convenient platform for studies aimed at the development of ZIKV vaccines (live attenuated and inactivated) and therapeutics.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) or diagnostics for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D. at peter.soukas@nih.gov or 301-594-8730.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) or diagnostics for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D. at peter.soukas@nih.gov or 301-594-8730.

# data[].attributes.field_commercial_applications.value
Diagnostics

Vaccines

Development of therapeutics

# data[].attributes.field_commercial_applications.processed
Diagnostics

Vaccines

Development of therapeutics

# data[].attributes.field_competitive_advantages.value
Use in development of flavivirus vaccines

Virus growth in various cell lines

Developing and developed world research tool

# data[].attributes.field_competitive_advantages.processed
Use in development of flavivirus vaccines

Virus growth in various cell lines

Developing and developed world research tool

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development&body=Please send me information about technology [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development&body=Please send me information about technology [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development.

# data[].attributes.field_publications[].value
Tsetsarkin KA, et al.

# data[].attributes.field_publications[].processed
Tsetsarkin KA, et al.

# data[].attributes.field_technology_names[]
Full-length Infectious CDNA Clone Of Zika Virus From The 2015 Epidemic In Brazil As A Genetic Platform For Studies Of Virus-Host Interactions And Vaccine Development

# data[].attributes.title
Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines

# data[].attributes.body.value
Influenza virus is a major public health concern, causing up to 500,000 deaths annually. The current strategy of reformulating vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel influenza viruses with pandemic potential. Thus, there is a great need for a vaccine that provides “universal” protection against influenza viruses.

This technology relates to a broadly protective, universal influenza vaccine candidate composed of a mixture of virus-like particles (VLPs) expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes. Vaccinating animals with a mixture of VLPs expressing four or more hemagglutinin subtypes provides broad and heterosubtypic protection against lethal challenge with influenza virus strains in both mice and ferrets. This vaccine technology has great potential to provide protection against both annual epidemic and pandemic-potential influenza viruses. This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.

# data[].attributes.body.processed
Influenza virus is a major public health concern, causing up to 500,000 deaths annually. The current strategy of reformulating vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel influenza viruses with pandemic potential. Thus, there is a great need for a vaccine that provides “universal” protection against influenza viruses.

This technology relates to a broadly protective, universal influenza vaccine candidate composed of a mixture of virus-like particles (VLPs) expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes. Vaccinating animals with a mixture of VLPs expressing four or more hemagglutinin subtypes provides broad and heterosubtypic protection against lethal challenge with influenza virus strains in both mice and ferrets. This vaccine technology has great potential to provide protection against both annual epidemic and pandemic-potential influenza viruses. This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation. For collaboration opportunities, please contact Dr. Elizabeth Pitts at elizabeth.pitts@nih.gov or 240-669-5299.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation. For collaboration opportunities, please contact Dr. Elizabeth Pitts at elizabeth.pitts@nih.gov or 240-669-5299.

# data[].attributes.field_commercial_applications.value
Vaccines

# data[].attributes.field_commercial_applications.processed
Vaccines

# data[].attributes.field_competitive_advantages.value
Broad/universal protection against influenza viruses

Does not require reformulating vaccine each year as is currently necessary with vaccines available on the market

Can potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza viruses

# data[].attributes.field_competitive_advantages.processed
Broad/universal protection against influenza viruses

Does not require reformulating vaccine each year as is currently necessary with vaccines available on the market

Can potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza viruses

# data[].attributes.field_licensingcontact_hrefs[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines&body=Please send me information about technology [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines.

# data[].attributes.field_licensingcontact_htmls[]
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].value
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Ganelina, Anna
ganelinaa@niaid.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines&body=Please send me information about technology [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines.

# data[].attributes.field_patents[].value
US Patent 10,130,700
Filed on 2016-12-09
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,130,700
Filed on 2016-12-09
Status: Issued

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2015/029843
Filed on 2015-05-08
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2015/029843
Filed on 2015-05-08
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/014,821
Filed on 2014-06-20
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/014,821
Filed on 2014-06-20
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 10,130,700
Filed on 2016-12-09
Status: Issued

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2015/029843
Filed on 2015-05-08
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/014,821
Filed on 2014-06-20
Status: Abandoned

# data[].attributes.field_patent_titles[]
Polyvalent Influenza Virus-Like Particles (VLPS) And Use As Vaccines

# data[].attributes.field_patent_titles[]
Polyvalent Influenza Virus-Like Particles (VLPS) And Use as Vaccines

# data[].attributes.field_patent_titles[]
Polyvalent Influenza Virus-Like Particles (VLPs) And Use as Vaccines

# data[].attributes.field_publications[].value
Schwartzman LM, et al.

# data[].attributes.field_publications[].processed
Schwartzman LM, et al.

# data[].attributes.field_technology_names[]
Development Of A Polyvalent Viral Like Particle Vaccine To Provide Broad Protection Against Influenza A Viruses Of Different Subtypes

# data[].attributes.title
Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies

# data[].attributes.body.value
Description of Technology:

Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA. Gene therapy using the CRX-AAV vector to retinal organoids derived from induced pluripotent stem cells (iPSCs) of a patient with the dominant CRX-I138fs mutation partially restored expression of visual opsins and other phototransduction genes as revealed by immunohistochemistry and single cell RNA-sequencing. Retinal organoids from iPSCs of a second dominant CRX-LCA patient carrying a K88N mutation also revealed loss of expression of opsins and phototransduction genes as a common phenotype, which could be alleviated by AAV-mediated overexpression of CRX.

Potential Commercial Applications:

Early onset blindness, including Leber congenital amaurosis

Gene therapy of CRX retinopathies; i.e., patients with a mutation in the CRX gene

Competitive Advantages:

Promising commercial potential given that there are no current treatments for CRX-retinopathies

Gene therapy by delivering CRX should restore photoreceptor structure and function

Existing commercial interest and an established regulatory path for directly administered gene therapy targeting an ophthalmic disease caused by mutations in a specific gene: In 2017, Luxturna (voretigene neparvovec-rzyl) was FDA approved for an inherited form of vision loss (confirmed biallelic RPE65 mutation-associated retinal dystrophy) that may result in blindness

# data[].attributes.body.processed
Description of Technology:

Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA. Gene therapy using the CRX-AAV vector to retinal organoids derived from induced pluripotent stem cells (iPSCs) of a patient with the dominant CRX-I138fs mutation partially restored expression of visual opsins and other phototransduction genes as revealed by immunohistochemistry and single cell RNA-sequencing. Retinal organoids from iPSCs of a second dominant CRX-LCA patient carrying a K88N mutation also revealed loss of expression of opsins and phototransduction genes as a common phenotype, which could be alleviated by AAV-mediated overexpression of CRX.

Potential Commercial Applications:

Early onset blindness, including Leber congenital amaurosis

Gene therapy of CRX retinopathies; i.e., patients with a mutation in the CRX gene

Competitive Advantages:

Promising commercial potential given that there are no current treatments for CRX-retinopathies

Gene therapy by delivering CRX should restore photoreceptor structure and function

Existing commercial interest and an established regulatory path for directly administered gene therapy targeting an ophthalmic disease caused by mutations in a specific gene: In 2017, Luxturna (voretigene neparvovec-rzyl) was FDA approved for an inherited form of vision loss (confirmed biallelic RPE65 mutation-associated retinal dystrophy) that may result in blindness

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/962,732
Filed on 2020-01-17
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/962,732
Filed on 2020-01-17
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/013733
Filed on 2021-01-15
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/013733
Filed on 2021-01-15
Status: Expired

# data[].attributes.field_patents[].value
US
National Stage 17/789,729
Filed on 2022-06-28
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 17/789,729
Filed on 2022-06-28
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2021208631
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2021208631
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3165922
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3165922
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 21705324.8
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 21705324.8
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patents[].value
Japan
National Stage 2022-540642
Filed on 2021-01-15
Status: Issued

# data[].attributes.field_patents[].processed
Japan
National Stage 2022-540642
Filed on 2021-01-15
Status: Issued

# data[].attributes.field_patents[].value
US
Divisional (DIV) None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
US
Divisional (DIV) None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/962,732
Filed on 2020-01-17
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/013733
Filed on 2021-01-15
Status: Expired

# data[].attributes.field_patent_htmls[]
US
National Stage 17/789,729
Filed on 2022-06-28
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2021208631
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3165922
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 21705324.8
Filed on 2021-01-15
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2022-540642
Filed on 2021-01-15
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Divisional (DIV) None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_titles[]
Gene Therapy For Treatment Of CRX-associated Retinopathies

# data[].attributes.field_patent_titles[]
GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES

# data[].attributes.field_patent_titles[]
GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES

# data[].attributes.field_patent_titles[]
GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES

# data[].attributes.field_patent_titles[]
GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES

# data[].attributes.field_patent_titles[]
GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES

# data[].attributes.field_patent_titles[]
GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES

# data[].attributes.field_patent_titles[]
GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES

# data[].attributes.field_technology_names[]
Gene Therapy For Treatment Of CRX-associated Retinopathies

# data[].attributes.title
A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients

# data[].attributes.body.value
This technology includes the incorporation of a magnetic field gradient waveform (consisting of two or more pulses) between excitation and encoding to eliminate signal from moving fluid for imaging applications. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. Motion of this water due to ultrasound vibrations, convection, and circulation between sonications causes diffuse artifacts in images, which can compromise clinical outcomes. PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures.

# data[].attributes.body.processed
This technology includes the incorporation of a magnetic field gradient waveform (consisting of two or more pulses) between excitation and encoding to eliminate signal from moving fluid for imaging applications. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. Motion of this water due to ultrasound vibrations, convection, and circulation between sonications causes diffuse artifacts in images, which can compromise clinical outcomes. PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures.

# data[].attributes.field_collaboration_description.value
We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.

# data[].attributes.field_collaboration_description.processed
We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.

# data[].attributes.field_commercial_applications.value
Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value.

# data[].attributes.field_commercial_applications.processed
Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value.

# data[].attributes.field_competitive_advantages.value
The proposed solution:

does not require any additional hardware, materials, or changes in clinical setup

can easily be incorporated into the existing product pulse sequences, and therefore adds no additional cost for implementation

does not impact image acquisition time under most practical circumstances

# data[].attributes.field_competitive_advantages.processed
The proposed solution:

does not require any additional hardware, materials, or changes in clinical setup

can easily be incorporated into the existing product pulse sequences, and therefore adds no additional cost for implementation

does not impact image acquisition time under most practical circumstances

# data[].attributes.field_inventor_companies[]
National Heart, Lung, and Blood Institute (NHLBI)

# data[].attributes.field_licensingcontact_depts[]
Office of Technology Transfer and Development

# data[].attributes.field_licensingcontact_hrefs[]
shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients.

# data[].attributes.field_licensingcontact_htmls[]
Shmilovich, Michael
shmilovm@nih.gov

# data[].attributes.field_licensing_contacts[].value
Shmilovich, Michael
shmilovm@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Shmilovich, Michael
shmilovm@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients.

# data[].attributes.field_technology_names[]
A Method To Remove Fluid-motion Related Artifacts In Magnetic Resonance Thermometry Images Using Magnetic Field Gradients

# data[].attributes.field_technology_owners[]
National Heart, Lung, and Blood Institute (NHLBI), Siemens Medical Solutions USA Inc., Siemens Medical Solutions USA, Inc.

# data[].attributes.title
RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS).

This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition that leads to vision impairment and is caused by mutations in the Rs1 gene. The development of this mouse model addresses a significant gap in the understanding of the biological mechanisms underlying XLRS, allowing researchers to explore gene and protein functions in a controlled environment. This model is crucial for testing potential therapeutic approaches aimed at restoring vision in affected individuals.

The RS-1 knockout mouse model provides a unique platform for biological studies, enabling researchers to investigate the effects of the Rs1 gene and its protein in vivo. This model is particularly valuable for pharmaceutical companies and academic institutions focused on developing treatments for retinal diseases. By utilizing this model, stakeholders can gain insights into disease progression and evaluate the efficacy of new therapeutic strategies, ultimately leading to advancements in patient care.

We are seeking licensing opportunities for this innovative technology, which has already been utilized in various laboratory studies. Collaborators and licensees will have the chance to leverage this model for their research and development efforts, contributing to the advancement of therapies for XLRS and related conditions. We welcome discussions on potential partnerships that can enhance the impact of this technology in the field of ophthalmology.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS).

This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition that leads to vision impairment and is caused by mutations in the Rs1 gene. The development of this mouse model addresses a significant gap in the understanding of the biological mechanisms underlying XLRS, allowing researchers to explore gene and protein functions in a controlled environment. This model is crucial for testing potential therapeutic approaches aimed at restoring vision in affected individuals.

The RS-1 knockout mouse model provides a unique platform for biological studies, enabling researchers to investigate the effects of the Rs1 gene and its protein in vivo. This model is particularly valuable for pharmaceutical companies and academic institutions focused on developing treatments for retinal diseases. By utilizing this model, stakeholders can gain insights into disease progression and evaluate the efficacy of new therapeutic strategies, ultimately leading to advancements in patient care.

We are seeking licensing opportunities for this innovative technology, which has already been utilized in various laboratory studies. Collaborators and licensees will have the chance to leverage this model for their research and development efforts, contributing to the advancement of therapies for XLRS and related conditions. We welcome discussions on potential partnerships that can enhance the impact of this technology in the field of ophthalmology.

# data[].attributes.field_commercial_applications.value
•	Research on X-linked retinoschisis (XLRS)
•	Development of gene therapies for retinal diseases
•	Testing of pharmacological interventions in a live model
•	Studies on retinal degeneration mechanisms

# data[].attributes.field_commercial_applications.processed
•	Research on X-linked retinoschisis (XLRS)
•	Development of gene therapies for retinal diseases
•	Testing of pharmacological interventions in a live model
•	Studies on retinal degeneration mechanisms

# data[].attributes.field_competitive_advantages.value
•	Unique transgenic model specifically for XLRS research
•	Enables in vivo studies of Rs1 gene and protein function
•	Facilitates testing of therapeutic approaches for retinal diseases
•	Established publication record demonstrating model efficacy

# data[].attributes.field_competitive_advantages.processed
•	Unique transgenic model specifically for XLRS research
•	Enables in vivo studies of Rs1 gene and protein function
•	Facilitates testing of therapeutic approaches for retinal diseases
•	Established publication record demonstrating model efficacy

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research&body=Please send me information about technology [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research&body=Please send me information about technology [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_technology_names[]
RS-1 Knockout Mouse Model Of X-linked Retinoschisis (XLRS)

# data[].attributes.title
Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.

This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms of glaucoma and screen for therapeutic agents. Glaucoma, a leading cause of blindness, is often associated with mutations in the myocilin gene, but the exact mechanisms by which these mutations lead to cell death are not fully understood. By utilizing these cell lines, researchers can investigate how mutant myocilin induces endoplasmic reticulum stress and apoptosis, particularly under oxidative stress conditions. This understanding could pave the way for the development of targeted therapies that mitigate the effects of these mutations and improve patient outcomes.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.

This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms of glaucoma and screen for therapeutic agents. Glaucoma, a leading cause of blindness, is often associated with mutations in the myocilin gene, but the exact mechanisms by which these mutations lead to cell death are not fully understood. By utilizing these cell lines, researchers can investigate how mutant myocilin induces endoplasmic reticulum stress and apoptosis, particularly under oxidative stress conditions. This understanding could pave the way for the development of targeted therapies that mitigate the effects of these mutations and improve patient outcomes.

# data[].attributes.field_commercial_applications.value
•	Drug discovery and development for glaucoma treatments.
•	Research into the molecular mechanisms of glaucoma pathogenesis.
•	Screening for compounds that can reduce oxidative stress in retinal cells.
•	Development of personalized medicine approaches for patients with myocilin mutations.

# data[].attributes.field_commercial_applications.processed
•	Drug discovery and development for glaucoma treatments.
•	Research into the molecular mechanisms of glaucoma pathogenesis.
•	Screening for compounds that can reduce oxidative stress in retinal cells.
•	Development of personalized medicine approaches for patients with myocilin mutations.

# data[].attributes.field_competitive_advantages.value
•	Enables high-throughput screening of potential therapeutic agents targeting myocilin mutations.
•	Provides a controlled environment to study the effects of oxidative stress on cell viability.
•	Facilitates the understanding of the molecular mechanisms underlying myocilin-induced glaucoma.
•	Offers a unique model for testing drug efficacy and safety in a relevant biological context.

# data[].attributes.field_competitive_advantages.processed
•	Enables high-throughput screening of potential therapeutic agents targeting myocilin mutations.
•	Provides a controlled environment to study the effects of oxidative stress on cell viability.
•	Facilitates the understanding of the molecular mechanisms underlying myocilin-induced glaucoma.
•	Offers a unique model for testing drug efficacy and safety in a relevant biological context.

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening&body=Please send me information about technology [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening&body=Please send me information about technology [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_publications[].value
Joe MK, et al., 2010 (PMID: 20382707)

# data[].attributes.field_publications[].processed
Joe MK, et al., 2010 (PMID: 20382707)

# data[].attributes.field_technology_names[]
ManufacturersExpression Of Myocilin Mutants Sensitizes Cells To Oxidative Stress-Induced Apoptosis

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), PTC Therapeutics, Inc.

# data[].attributes.title
iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.

This technology includes a novel protocol for differentiating induced pluripotent stem cells (iPSCs) into fibroblasts and endothelial cells, which are crucial for tissue engineering and regenerative medicine applications. Current methods for generating these cell types can be inefficient and inconsistent, leading to challenges in research and therapeutic applications. This protocol aims to streamline the differentiation process, enhancing the yield and quality of the derived cells.

The technical solution leverages optimized culture conditions and growth factors to promote the efficient differentiation of iPSCs into fibroblasts and endothelial cells. This is significant because it addresses the growing demand for reliable and reproducible cell sources in research and clinical settings. By providing a standardized method, this technology can facilitate advancements in tissue engineering, drug testing, and regenerative therapies.

The licensing opportunity for this technology is open to partnerships with companies and research institutions interested in cell therapy, regenerative medicine, and related fields. Collaborators can expect to engage in co-development efforts to further refine and commercialize the protocol, ensuring its applicability in various biomedical applications.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.

This technology includes a novel protocol for differentiating induced pluripotent stem cells (iPSCs) into fibroblasts and endothelial cells, which are crucial for tissue engineering and regenerative medicine applications. Current methods for generating these cell types can be inefficient and inconsistent, leading to challenges in research and therapeutic applications. This protocol aims to streamline the differentiation process, enhancing the yield and quality of the derived cells.

The technical solution leverages optimized culture conditions and growth factors to promote the efficient differentiation of iPSCs into fibroblasts and endothelial cells. This is significant because it addresses the growing demand for reliable and reproducible cell sources in research and clinical settings. By providing a standardized method, this technology can facilitate advancements in tissue engineering, drug testing, and regenerative therapies.

The licensing opportunity for this technology is open to partnerships with companies and research institutions interested in cell therapy, regenerative medicine, and related fields. Collaborators can expect to engage in co-development efforts to further refine and commercialize the protocol, ensuring its applicability in various biomedical applications.

# data[].attributes.field_commercial_applications.value
•	Regenerative medicine
•	Tissue engineering
•	Drug testing and development
•	Cell therapy
•	Research in developmental biology

# data[].attributes.field_commercial_applications.processed
•	Regenerative medicine
•	Tissue engineering
•	Drug testing and development
•	Cell therapy
•	Research in developmental biology

# data[].attributes.field_competitive_advantages.value
•	Streamlined differentiation process for iPSCs into fibroblasts and endothelial cells
•	High yield and quality of differentiated cells
•	Standardized protocol enhances reproducibility
•	Potential for broad applications in regenerative medicine and tissue engineering
•	Addresses current inefficiencies in existing methods

# data[].attributes.field_competitive_advantages.processed
•	Streamlined differentiation process for iPSCs into fibroblasts and endothelial cells
•	High yield and quality of differentiated cells
•	Standardized protocol enhances reproducibility
•	Potential for broad applications in regenerative medicine and tissue engineering
•	Addresses current inefficiencies in existing methods

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation&body=Please send me information about technology [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation&body=Please send me information about technology [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_technology_names[]
Fibroblasts, Pericytes, And Endothelial Cells As Generated By An IPSC Differentiation Protocol

# data[].attributes.title
Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.

This technology includes a thermosensitive hydrogel bioink designed for vascular tissue engineering. The hydrogel is unique in that it transitions from a gel state at room temperature to a liquid state at physiological temperatures, allowing for easy handling and application in bioprinting. The primary challenge in tissue engineering is the formation of functional blood vessels, which is critical for tissue viability. Current methods often involve harmful chemical crosslinkers or UV light, which can compromise cell viability. This hydrogel, made from fibrinogen and gelatin, promotes blood vessel formation by providing a supportive extracellular matrix without the use of harmful agents.

The technical solution involves a combination of fibrinogen, which serves as a provisional extracellular matrix, and gelatin, which adjusts viscosity with temperature changes. This innovative approach not only enhances cell viability but also reduces material costs, making it a compelling option for researchers and companies in the field of tissue engineering. You should care about this technology because it represents a significant advancement in bioprinting techniques, enabling the creation of vascularized tissues that closely mimic natural environments.

The licensing opportunity for this technology is open to interested parties looking to collaborate in further development or commercialization. The inventors are seeking partners who can help bring this innovative bioink to market, potentially leading to groundbreaking applications in regenerative medicine and tissue engineering.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.

This technology includes a thermosensitive hydrogel bioink designed for vascular tissue engineering. The hydrogel is unique in that it transitions from a gel state at room temperature to a liquid state at physiological temperatures, allowing for easy handling and application in bioprinting. The primary challenge in tissue engineering is the formation of functional blood vessels, which is critical for tissue viability. Current methods often involve harmful chemical crosslinkers or UV light, which can compromise cell viability. This hydrogel, made from fibrinogen and gelatin, promotes blood vessel formation by providing a supportive extracellular matrix without the use of harmful agents.

The technical solution involves a combination of fibrinogen, which serves as a provisional extracellular matrix, and gelatin, which adjusts viscosity with temperature changes. This innovative approach not only enhances cell viability but also reduces material costs, making it a compelling option for researchers and companies in the field of tissue engineering. You should care about this technology because it represents a significant advancement in bioprinting techniques, enabling the creation of vascularized tissues that closely mimic natural environments.

The licensing opportunity for this technology is open to interested parties looking to collaborate in further development or commercialization. The inventors are seeking partners who can help bring this innovative bioink to market, potentially leading to groundbreaking applications in regenerative medicine and tissue engineering.

# data[].attributes.field_commercial_applications.value
•	Vascular tissue engineering
•	Bioprinting of complex tissue structures
•	Angiogenesis assays for research and drug testing
•	Regenerative medicine applications

# data[].attributes.field_commercial_applications.processed
•	Vascular tissue engineering
•	Bioprinting of complex tissue structures
•	Angiogenesis assays for research and drug testing
•	Regenerative medicine applications

# data[].attributes.field_competitive_advantages.value
•	Thermosensitive properties allow for easy handling and application in bioprinting
•	Promotes cell viability by avoiding harmful crosslinking methods
•	Biodegradable materials that can be converted to native extracellular matrix by embedded cells
•	Cost-effective compared to traditional bioinks

# data[].attributes.field_competitive_advantages.processed
•	Thermosensitive properties allow for easy handling and application in bioprinting
•	Promotes cell viability by avoiding harmful crosslinking methods
•	Biodegradable materials that can be converted to native extracellular matrix by embedded cells
•	Cost-effective compared to traditional bioinks

# data[].attributes.field_inventor_companies[]
National Center for Advancing Translational Sciences

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_publications[].value
Min Jae Song et al., 2022 (PMID: 36550275)

# data[].attributes.field_publications[].processed
Min Jae Song et al., 2022 (PMID: 36550275)

# data[].attributes.field_technology_names[]
Fibrin And Gelatin-based Bioink And Associated Supporting Fibrin Hydrogel

# data[].attributes.field_technology_owners[]
National Center for Advancing Translational Sciences, National Eye Institute (NEI), NCATS - NCGC

# data[].attributes.title
Interferon Gamma for Retinal Fluid Absorption Restoration

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.

This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects of fluid accumulation under the retina caused by small molecule cancer therapeutic drugs like Meki. The problem arises when cancer treatments, particularly MAP Kinase/ERK Kinase Inhibitors, lead to unwanted fluid build-up, which can impair vision and overall retinal health. This technology addresses a significant challenge in ocular health by providing a potential therapeutic solution to mitigate these side effects of cancer treatment.

The technical solution involves leveraging the previously established method of fluid transport across RPE cells, enhanced by the application of Interferon gamma. This approach not only aims to alleviate fluid accumulation but also seeks to improve the overall efficacy of cancer therapies by minimizing their ocular side effects. You should care about this technology because it represents a novel intersection of oncology and ophthalmology, potentially improving patient outcomes for those undergoing cancer treatment.

Currently, the National Eye Institute (NEI) is seeking collaborative support to fund or provide a source of Interferon gamma for larger clinical trials. There is an opportunity for licensing this technology, especially as NEI is in discussions with potential partners, including a start-up and Merck, to further clinical trials related to this innovative approach. This presents a unique chance for collaboration and investment in a promising therapeutic avenue.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.

This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects of fluid accumulation under the retina caused by small molecule cancer therapeutic drugs like Meki. The problem arises when cancer treatments, particularly MAP Kinase/ERK Kinase Inhibitors, lead to unwanted fluid build-up, which can impair vision and overall retinal health. This technology addresses a significant challenge in ocular health by providing a potential therapeutic solution to mitigate these side effects of cancer treatment.

The technical solution involves leveraging the previously established method of fluid transport across RPE cells, enhanced by the application of Interferon gamma. This approach not only aims to alleviate fluid accumulation but also seeks to improve the overall efficacy of cancer therapies by minimizing their ocular side effects. You should care about this technology because it represents a novel intersection of oncology and ophthalmology, potentially improving patient outcomes for those undergoing cancer treatment.

Currently, the National Eye Institute (NEI) is seeking collaborative support to fund or provide a source of Interferon gamma for larger clinical trials. There is an opportunity for licensing this technology, especially as NEI is in discussions with potential partners, including a start-up and Merck, to further clinical trials related to this innovative approach. This presents a unique chance for collaboration and investment in a promising therapeutic avenue.

# data[].attributes.field_commercial_applications.value
•	Treatment of fluid accumulation under the retina in cancer patients
•	Enhancement of cancer therapy efficacy by reducing ocular side effects
•	Potential use in other retinal diseases associated with fluid dysregulation
•	Research applications in the field of ocular pharmacology
•	Development of combination therapies for cancer and retinal health

# data[].attributes.field_commercial_applications.processed
•	Treatment of fluid accumulation under the retina in cancer patients
•	Enhancement of cancer therapy efficacy by reducing ocular side effects
•	Potential use in other retinal diseases associated with fluid dysregulation
•	Research applications in the field of ocular pharmacology
•	Development of combination therapies for cancer and retinal health

# data[].attributes.field_competitive_advantages.value
•	Utilizes a well-studied cytokine (Interferon gamma) for a novel application in retinal health
•	Addresses a significant unmet need in patients undergoing cancer treatment
•	Potential for improved patient outcomes by mitigating side effects of cancer therapies
•	Established preliminary clinical trial data supporting efficacy
•	Collaboration opportunities with established pharmaceutical companies like Merck

# data[].attributes.field_competitive_advantages.processed
•	Utilizes a well-studied cytokine (Interferon gamma) for a novel application in retinal health
•	Addresses a significant unmet need in patients undergoing cancer treatment
•	Potential for improved patient outcomes by mitigating side effects of cancer therapies
•	Established preliminary clinical trial data supporting efficacy
•	Collaboration opportunities with established pharmaceutical companies like Merck

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration&body=Please send me information about technology [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration&body=Please send me information about technology [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/721,810
Filed on 2012-11-02
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/721,810
Filed on 2012-11-02
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2013/068056
Filed on 2013-11-01
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2013/068056
Filed on 2013-11-01
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2013337702
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].processed
Australia
National Stage 2013337702
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].value
Canada
National Stage 2890238
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].processed
Canada
National Stage 2890238
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].value
European Patent
National Stage 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
US
National Stage 14/440,218
Filed on 2015-05-01
Status: Abandoned

# data[].attributes.field_patents[].processed
US
National Stage 14/440,218
Filed on 2015-05-01
Status: Abandoned

# data[].attributes.field_patents[].value
Germany
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
Ireland
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
Ireland
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/721,810
Filed on 2012-11-02
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2013/068056
Filed on 2013-11-01
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2013337702
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2890238
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
US
National Stage 14/440,218
Filed on 2015-05-01
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
Ireland
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_titles[]
METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT DURING TREATMENT WITH A MEK INHIBITOR

# data[].attributes.field_patent_titles[]
Methods of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_technology_names[]
Interferon Gamma Restores Retinal Pigment Epithelial (RPE) Fluid Absorption Suppressed By Small Molecule Cancer Therapeutic Drug Meki (Merck)

# data[].attributes.field_technology_owners[]
Dupont Merck Pharmaceutical Company, National Eye Institute (NEI)

# data[].attributes.title
Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.

This technology includes the use of Interferon-gamma (IFN-y) as a therapeutic agent to inhibit the proliferation and migration of human retinal pigment epithelial (RPE) cells, which is crucial in treating proliferative eye diseases such as age-related macular degeneration and proliferative vitreoretinopathy. The problem at hand is that abnormal RPE cell behavior is linked to severe ocular diseases that can lead to vision loss, affecting millions of individuals, particularly the elderly. The inventors have discovered that IFN-y can significantly reduce this abnormal cell activity, providing a potential treatment pathway for these debilitating conditions.

The technical solution involves intraocular injections of IFN-y, which have shown promise in halting excessive RPE proliferation and migration, thereby preventing the formation of abnormal tissues in the eye. This technology is important because it addresses a significant unmet medical need in ophthalmology, offering a novel approach to managing diseases that currently have limited treatment options. By targeting the underlying cellular mechanisms, this therapy could improve patient outcomes and reduce the burden of vision loss associated with these conditions.

The licensing opportunity for this technology is aimed at pharmaceutical companies and research institutions interested in developing new treatments for ocular diseases. The inventors are seeking partners for co-development and commercialization, emphasizing the potential for collaborative efforts to bring this innovative therapy to market. This collaboration could involve further clinical trials and research to validate the efficacy and safety of IFN-y in treating proliferative eye diseases.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.

This technology includes the use of Interferon-gamma (IFN-y) as a therapeutic agent to inhibit the proliferation and migration of human retinal pigment epithelial (RPE) cells, which is crucial in treating proliferative eye diseases such as age-related macular degeneration and proliferative vitreoretinopathy. The problem at hand is that abnormal RPE cell behavior is linked to severe ocular diseases that can lead to vision loss, affecting millions of individuals, particularly the elderly. The inventors have discovered that IFN-y can significantly reduce this abnormal cell activity, providing a potential treatment pathway for these debilitating conditions.

The technical solution involves intraocular injections of IFN-y, which have shown promise in halting excessive RPE proliferation and migration, thereby preventing the formation of abnormal tissues in the eye. This technology is important because it addresses a significant unmet medical need in ophthalmology, offering a novel approach to managing diseases that currently have limited treatment options. By targeting the underlying cellular mechanisms, this therapy could improve patient outcomes and reduce the burden of vision loss associated with these conditions.

The licensing opportunity for this technology is aimed at pharmaceutical companies and research institutions interested in developing new treatments for ocular diseases. The inventors are seeking partners for co-development and commercialization, emphasizing the potential for collaborative efforts to bring this innovative therapy to market. This collaboration could involve further clinical trials and research to validate the efficacy and safety of IFN-y in treating proliferative eye diseases.

# data[].attributes.field_commercial_applications.value
•	Treatment of age-related macular degeneration
•	Management of proliferative vitreoretinopathy
•	Therapeutic intervention for proliferative diabetic retinopathy
•	Potential use in retinal detachment cases

# data[].attributes.field_commercial_applications.processed
•	Treatment of age-related macular degeneration
•	Management of proliferative vitreoretinopathy
•	Therapeutic intervention for proliferative diabetic retinopathy
•	Potential use in retinal detachment cases

# data[].attributes.field_competitive_advantages.value
•	Significant inhibition of RPE cell proliferation and migration
•	Potential to treat multiple proliferative eye diseases
•	Novel therapeutic approach with limited current competition
•	Intraocular delivery method for targeted treatment

# data[].attributes.field_competitive_advantages.processed
•	Significant inhibition of RPE cell proliferation and migration
•	Potential to treat multiple proliferative eye diseases
•	Novel therapeutic approach with limited current competition
•	Intraocular delivery method for targeted treatment

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases&body=Please send me information about technology [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases&body=Please send me information about technology [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/089,157
Filed on 2008-08-15
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/089,157
Filed on 2008-08-15
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2009/053808
Filed on 2009-08-14
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2009/053808
Filed on 2009-08-14
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2009281849
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
Australia
National Stage 2009281849
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
Canada
National Stage 2734185
Filed on 2011-02-14
Status: Issued

# data[].attributes.field_patents[].processed
Canada
National Stage 2734185
Filed on 2011-02-14
Status: Issued

# data[].attributes.field_patents[].value
European Patent
National Stage 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
US Patent 8,697,046
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,697,046
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
US Patent 9,486,502
Filed on 2014-04-14
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 9,486,502
Filed on 2014-04-14
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/089,157
Filed on 2008-08-15
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2009/053808
Filed on 2009-08-14
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2009281849
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2734185
Filed on 2011-02-14
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 8,697,046
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 9,486,502
Filed on 2014-04-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_titles[]
METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE

# data[].attributes.field_patent_titles[]
METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE

# data[].attributes.field_patent_titles[]
Methods For Using Interferon Gamma To Absorb Fluid Form The Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for Using Interferon Gamma to Absorb Fluid From the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE

# data[].attributes.field_patent_titles[]
Methods of Using Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_technology_names[]
Interferon Gamma Inhibits Human Retinal Pigment Epithelium Proliferation And Migration

# data[].attributes.title
Gene Therapy for Leber Congenital Amaurosis

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.

This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited eye disorder that leads to significant vision loss in infants, affecting approximately 20,000 individuals worldwide. Currently, there are no effective treatments available for LCA, particularly for the CEP290 mutation, which accounts for 20-25% of cases. Our research has identified a functional subunit of the CEP290 gene that can be effectively delivered to the retina using an adeno-associated viral (AAV) vector, overcoming the limitations of previous gene therapy attempts that struggled with the large size of the full-length CEP290 gene. This breakthrough offers hope for restoring vision in patients suffering from this debilitating condition.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.

This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited eye disorder that leads to significant vision loss in infants, affecting approximately 20,000 individuals worldwide. Currently, there are no effective treatments available for LCA, particularly for the CEP290 mutation, which accounts for 20-25% of cases. Our research has identified a functional subunit of the CEP290 gene that can be effectively delivered to the retina using an adeno-associated viral (AAV) vector, overcoming the limitations of previous gene therapy attempts that struggled with the large size of the full-length CEP290 gene. This breakthrough offers hope for restoring vision in patients suffering from this debilitating condition.

# data[].attributes.field_commercial_applications.value
•	Therapeutic to treat Leber congenital amaurosis

# data[].attributes.field_commercial_applications.processed
•	Therapeutic to treat Leber congenital amaurosis

# data[].attributes.field_competitive_advantages.value
•	Established FDA approval route as gene therapy (based on Luxturna)
•	Previous attempts at treating CEP290-related LCA by gene therapy have been unsuccessful because of difficulty in delivering the full length CEP290 gene with a single vector. The present invention uses an AAV construct with a truncated portion of the CEP290 coding region that expresses functional protein to the photoreceptors.

# data[].attributes.field_competitive_advantages.processed
•	Established FDA approval route as gene therapy (based on Luxturna)
•	Previous attempts at treating CEP290-related LCA by gene therapy have been unsuccessful because of difficulty in delivering the full length CEP290 gene with a single vector. The present invention uses an AAV construct with a truncated portion of the CEP290 coding region that expresses functional protein to the photoreceptors.

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5107] Gene Therapy for Leber Congenital Amaurosis&body=Please send me information about technology [TAB-5107] Gene Therapy for Leber Congenital Amaurosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5107] Gene Therapy for Leber Congenital Amaurosis&body=Please send me information about technology [TAB-5107] Gene Therapy for Leber Congenital Amaurosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/042,703
Filed on 2014-08-27
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/042,703
Filed on 2014-08-27
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2015/047209
Filed on 2015-08-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2015/047209
Filed on 2015-08-27
Status: Expired

# data[].attributes.field_patents[].value
US Patent 10,351,844
Filed on 2017-02-24
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,351,844
Filed on 2017-02-24
Status: Issued

# data[].attributes.field_patents[].value
Canada
National Stage 2959540
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
Canada
National Stage 2959540
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
European Patent
National Stage 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
US Patent 11,421,219
Filed on 2019-05-28
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 11,421,219
Filed on 2019-05-28
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/042,703
Filed on 2014-08-27
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2015/047209
Filed on 2015-08-27
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 10,351,844
Filed on 2017-02-24
Status: Issued

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2959540
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 11,421,219
Filed on 2019-05-28
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_titles[]
METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_publications[].value
Mookherjee S, et al., 2018 (PMID: 30332642)

# data[].attributes.field_publications[].processed
Mookherjee S, et al., 2018 (PMID: 30332642)

# data[].attributes.field_technology_names[]
A Novel Gene Therapy Vector For Treating CEP290-associated Leber Congenital Amaurosis

# data[].attributes.title
Immunosuppressive Exosomes for Treating Autoimmune Diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.

This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing regulatory B cells (Bregs) as a therapeutic treatment for autoimmune diseases such as uveitis and multiple sclerosis. Current therapies face challenges with dosing and bioavailability of IL-35, which is a weakly associated heterodimer that can easily dissociate. Our innovative approach utilizes exosomes that encapsulate both subunits of IL-27 and IL-35, ensuring a stable and effective delivery mechanism. This advancement addresses the critical need for reliable dosing and bioavailability in immunotherapy, making it a significant improvement over existing treatments.

The technical solution involves the isolation and application of exosomes that contain biologically active IL-27 and IL-35, which have shown efficacy in preclinical models by suppressing neuroinflammation and promoting regulatory immune responses. This technology is particularly relevant for C-level executives and directors in the biotech and pharmaceutical industries, as it opens new avenues for treating challenging autoimmune conditions with a novel delivery system that overcomes existing barriers in therapeutic administration.

We are seeking licensing opportunities for this groundbreaking technology, which has the potential to transform the treatment landscape for autoimmune diseases. Collaborators and licensees will benefit from access to a unique therapeutic platform that is ready for further development and commercialization. We invite interested parties to engage in discussions regarding potential partnerships and licensing agreements to bring this innovative therapy to market.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.

This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing regulatory B cells (Bregs) as a therapeutic treatment for autoimmune diseases such as uveitis and multiple sclerosis. Current therapies face challenges with dosing and bioavailability of IL-35, which is a weakly associated heterodimer that can easily dissociate. Our innovative approach utilizes exosomes that encapsulate both subunits of IL-27 and IL-35, ensuring a stable and effective delivery mechanism. This advancement addresses the critical need for reliable dosing and bioavailability in immunotherapy, making it a significant improvement over existing treatments.

The technical solution involves the isolation and application of exosomes that contain biologically active IL-27 and IL-35, which have shown efficacy in preclinical models by suppressing neuroinflammation and promoting regulatory immune responses. This technology is particularly relevant for C-level executives and directors in the biotech and pharmaceutical industries, as it opens new avenues for treating challenging autoimmune conditions with a novel delivery system that overcomes existing barriers in therapeutic administration.

We are seeking licensing opportunities for this groundbreaking technology, which has the potential to transform the treatment landscape for autoimmune diseases. Collaborators and licensees will benefit from access to a unique therapeutic platform that is ready for further development and commercialization. We invite interested parties to engage in discussions regarding potential partnerships and licensing agreements to bring this innovative therapy to market.

# data[].attributes.field_commercial_applications.value
•	Treatment for autoimmune diseases such as uveitis and multiple sclerosis
•	Potential applications in therapies for other inflammatory conditions like arthritis and graft-versus-host disease (GVHD)
•	Development of exosome-based immunotherapies for various neurological disorders

# data[].attributes.field_commercial_applications.processed
•	Treatment for autoimmune diseases such as uveitis and multiple sclerosis
•	Potential applications in therapies for other inflammatory conditions like arthritis and graft-versus-host disease (GVHD)
•	Development of exosome-based immunotherapies for various neurological disorders

# data[].attributes.field_competitive_advantages.value
•	Exosomes provide a stable delivery system for IL-27 and IL-35, overcoming dosing challenges associated with traditional therapies
•	The small size of exosomes (30-150 nm) allows for effective delivery across the blood-brain and blood-ocular barriers, enhancing therapeutic potential in neuroinflammatory diseases
•	Preclinical studies demonstrate significant efficacy in suppressing autoimmune responses and promoting regulatory immune cell expansion

# data[].attributes.field_competitive_advantages.processed
•	Exosomes provide a stable delivery system for IL-27 and IL-35, overcoming dosing challenges associated with traditional therapies
•	The small size of exosomes (30-150 nm) allows for effective delivery across the blood-brain and blood-ocular barriers, enhancing therapeutic potential in neuroinflammatory diseases
•	Preclinical studies demonstrate significant efficacy in suppressing autoimmune responses and promoting regulatory immune cell expansion

# data[].attributes.field_licensingcontact_htmls[]
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_licensing_contacts[].value
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/135,833
Filed on 2021-01-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/135,833
Filed on 2021-01-11
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/034778
Filed on 2021-05-28
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/034778
Filed on 2021-05-28
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2023-541862
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2023-541862
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3204551
Filed on 2023-07-07
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3204551
Filed on 2023-07-07
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2021417166
Filed on 2023-07-21
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2021417166
Filed on 2023-07-21
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/271,583
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/271,583
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 21742557.8
Filed on 2023-07-26
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 21742557.8
Filed on 2023-07-26
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/135,833
Filed on 2021-01-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/034778
Filed on 2021-05-28
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2023-541862
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3204551
Filed on 2023-07-07
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2021417166
Filed on 2023-07-21
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/271,583
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 21742557.8
Filed on 2023-07-26
Status: Pending

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_publications[].value
Choi JK, et al., 2025 (PMID: 40093899)

# data[].attributes.field_publications[].processed
Choi JK, et al., 2025 (PMID: 40093899)

# data[].attributes.field_publications[].value
Kang M, et al., 2020 (PMID: 32547555)

# data[].attributes.field_publications[].processed
Kang M, et al., 2020 (PMID: 32547555)

# data[].attributes.field_technology_names[]
Immunosuppressive Interleukin 35 And Interleukin 27- Producing Exosomes As A Therapeutic Treatment

# data[].attributes.title
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.

This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1), a protein crucial for retinal health, which has potential therapeutic applications for X-Linked Retinoschisis (XLRS). XLRS is a genetic condition that leads to severe vision loss due to the malfunction of the RS1 protein. Current treatment options are limited, and this technology aims to provide a novel approach by producing RS1 in a human cell line, ensuring proper post-translational modifications and reducing immunogenicity. The stable cell line, derived from ARPE-19 cells, allows for consistent and high-yield production of RS1, which can be utilized for both therapeutic and research purposes.

The technical solution involves the use of human ARPE-19 cells, which are known for their ability to produce and secrete proteins effectively. This cell line has been optimized to express RS1 and its variants, including mutant forms, under serum-free conditions, which is essential for therapeutic applications. The significance of this technology lies in its potential to improve patient outcomes for those suffering from XLRS by providing a reliable source of RS1 for treatment.

The licensing opportunity for this technology is open for collaboration with industry partners interested in ocular therapeutics. The inventors are seeking partners who can assist in further development and commercialization of the RS1 protein and its delivery systems, including encapsulated cell-based therapies and nanoparticle formulations for targeted delivery to the retina.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.

This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1), a protein crucial for retinal health, which has potential therapeutic applications for X-Linked Retinoschisis (XLRS). XLRS is a genetic condition that leads to severe vision loss due to the malfunction of the RS1 protein. Current treatment options are limited, and this technology aims to provide a novel approach by producing RS1 in a human cell line, ensuring proper post-translational modifications and reducing immunogenicity. The stable cell line, derived from ARPE-19 cells, allows for consistent and high-yield production of RS1, which can be utilized for both therapeutic and research purposes.

The technical solution involves the use of human ARPE-19 cells, which are known for their ability to produce and secrete proteins effectively. This cell line has been optimized to express RS1 and its variants, including mutant forms, under serum-free conditions, which is essential for therapeutic applications. The significance of this technology lies in its potential to improve patient outcomes for those suffering from XLRS by providing a reliable source of RS1 for treatment.

The licensing opportunity for this technology is open for collaboration with industry partners interested in ocular therapeutics. The inventors are seeking partners who can assist in further development and commercialization of the RS1 protein and its delivery systems, including encapsulated cell-based therapies and nanoparticle formulations for targeted delivery to the retina.

# data[].attributes.field_commercial_applications.value
•	Treatment for X-Linked Retinoschisis (XLRS)
•	Research applications in retinal cell biology
•	Development of protein delivery systems for ocular therapies
•	Large-scale production of RS1 for pharmaceutical use
•	Study of RS1 structure and function in various cellular contexts

# data[].attributes.field_commercial_applications.processed
•	Treatment for X-Linked Retinoschisis (XLRS)
•	Research applications in retinal cell biology
•	Development of protein delivery systems for ocular therapies
•	Large-scale production of RS1 for pharmaceutical use
•	Study of RS1 structure and function in various cellular contexts

# data[].attributes.field_competitive_advantages.value
•	High-yield production of human Retinoschisin (RS1) in a stable cell line
•	Utilization of human ARPE-19 cells ensures proper post-translational modifications
•	Serum-free production reduces immunogenicity risks
•	Potential for both therapeutic and research applications in retinal diseases
•	Ability to produce mutant forms of RS1 for functional studies

# data[].attributes.field_competitive_advantages.processed
•	High-yield production of human Retinoschisin (RS1) in a stable cell line
•	Utilization of human ARPE-19 cells ensures proper post-translational modifications
•	Serum-free production reduces immunogenicity risks
•	Potential for both therapeutic and research applications in retinal diseases
•	Ability to produce mutant forms of RS1 for functional studies

# data[].attributes.field_inventor_companies[]
National Institute on Deafness and Other Communication Disorders (NIDCD)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy&body=Please send me information about technology [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy&body=Please send me information about technology [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/049,749
Filed on 2020-07-09
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/049,749
Filed on 2020-07-09
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/040790
Filed on 2021-07-08
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/040790
Filed on 2021-07-08
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/049,749
Filed on 2020-07-09
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/040790
Filed on 2021-07-08
Status: Expired

# data[].attributes.field_patent_titles[]
CELL LINES THAT PRODUCE HUMAN RETINOSCHISIN PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
Cell Lines that Produce Human Retinoschisin Proteins and Uses Thereof

# data[].attributes.field_technology_names[]
Stable Cell Line For Large Scale Production Of Serum Free Human Retinoschisin And Its Mutant/discoidin Domain Variants In Mammalian Cell System, And Its Therapeutic Application For Ocular Cell/protein Therapy In XLRS

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD)

# data[].attributes.title
Advanced Gene Editing Technology for Therapeutic Applications

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.

This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited, often resulting in lifelong management rather than a cure. This technology offers a precise and efficient method to modify genes, potentially correcting the underlying causes of these disorders. By utilizing cutting-edge CRISPR technology, this solution not only enhances the accuracy of gene editing but also minimizes off-target effects, making it a safer option for therapeutic use. Stakeholders in the healthcare and biotechnology sectors should care about this technology as it represents a significant advancement in the pursuit of curative treatments for previously untreatable conditions. The licensing opportunity for this technology is open for collaboration with industry partners who are interested in further developing and commercializing these innovative therapeutic solutions. We are looking for partners who can contribute to the next stages of development and bring these therapies to market.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.

This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited, often resulting in lifelong management rather than a cure. This technology offers a precise and efficient method to modify genes, potentially correcting the underlying causes of these disorders. By utilizing cutting-edge CRISPR technology, this solution not only enhances the accuracy of gene editing but also minimizes off-target effects, making it a safer option for therapeutic use. Stakeholders in the healthcare and biotechnology sectors should care about this technology as it represents a significant advancement in the pursuit of curative treatments for previously untreatable conditions. The licensing opportunity for this technology is open for collaboration with industry partners who are interested in further developing and commercializing these innovative therapeutic solutions. We are looking for partners who can contribute to the next stages of development and bring these therapies to market.

# data[].attributes.field_commercial_applications.value
•	Treatment of genetic disorders
•	Development of personalized medicine
•	Research in gene function and regulation
•	Innovative therapeutic strategies for rare diseases

# data[].attributes.field_commercial_applications.processed
•	Treatment of genetic disorders
•	Development of personalized medicine
•	Research in gene function and regulation
•	Innovative therapeutic strategies for rare diseases

# data[].attributes.field_competitive_advantages.value
•	High precision in gene editing
•	Reduced off-target effects
•	Potential for curative therapies
•	Broad applicability across various genetic disorders

# data[].attributes.field_competitive_advantages.processed
•	High precision in gene editing
•	Reduced off-target effects
•	Potential for curative therapies
•	Broad applicability across various genetic disorders

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications&body=Please send me information about technology [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications&body=Please send me information about technology [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_technology_names[]
Pure IPCS-derived RPE Progenitor Cells For Drug Discovery And Disease Modeling

# data[].attributes.title
Innovative Gene Therapy for Retinal Diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.

This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and currently have limited treatment options. Our gene therapy targets the underlying genetic causes of these diseases, offering a potential cure rather than just symptomatic relief.

The technical solution involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to retinal cells. This method is significant because it not only addresses the root cause of the disease but also has the potential for long-lasting effects, reducing the need for frequent treatments. You should care about this technology because it represents a breakthrough in the field of ophthalmology, with the potential to restore vision and improve the quality of life for patients suffering from debilitating retinal conditions.

We are seeking licensing partners who are interested in co-developing this groundbreaking technology. The ideal partner would have experience in gene therapy and a commitment to advancing innovative treatments in ophthalmology. We are open to discussions regarding collaboration and are eager to explore opportunities that align with our goals for this technology.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.

This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and currently have limited treatment options. Our gene therapy targets the underlying genetic causes of these diseases, offering a potential cure rather than just symptomatic relief.

The technical solution involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to retinal cells. This method is significant because it not only addresses the root cause of the disease but also has the potential for long-lasting effects, reducing the need for frequent treatments. You should care about this technology because it represents a breakthrough in the field of ophthalmology, with the potential to restore vision and improve the quality of life for patients suffering from debilitating retinal conditions.

We are seeking licensing partners who are interested in co-developing this groundbreaking technology. The ideal partner would have experience in gene therapy and a commitment to advancing innovative treatments in ophthalmology. We are open to discussions regarding collaboration and are eager to explore opportunities that align with our goals for this technology.

# data[].attributes.field_commercial_applications.value
•	Treatment of age-related macular degeneration
•	Therapy for retinitis pigmentosa
•	Potential applications in other retinal disorders
•	Development of combination therapies with existing treatments

# data[].attributes.field_commercial_applications.processed
•	Treatment of age-related macular degeneration
•	Therapy for retinitis pigmentosa
•	Potential applications in other retinal disorders
•	Development of combination therapies with existing treatments

# data[].attributes.field_competitive_advantages.value
•	Targeted gene delivery using AAV vectors
•	Potential for long-lasting therapeutic effects
•	Addresses the root cause of retinal diseases
•	High safety profile with minimal side effects
•	Opportunity to significantly improve patient outcomes

# data[].attributes.field_competitive_advantages.processed
•	Targeted gene delivery using AAV vectors
•	Potential for long-lasting therapeutic effects
•	Addresses the root cause of retinal diseases
•	High safety profile with minimal side effects
•	Opportunity to significantly improve patient outcomes

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5116] Innovative Gene Therapy for Retinal Diseases&body=Please send me information about technology [TAB-5116] Innovative Gene Therapy for Retinal Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5116] Innovative Gene Therapy for Retinal Diseases&body=Please send me information about technology [TAB-5116] Innovative Gene Therapy for Retinal Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_publications[].value
Redmond TM, et al., 2000 (PMID: 10800710)

# data[].attributes.field_publications[].processed
Redmond TM, et al., 2000 (PMID: 10800710)

# data[].attributes.title
Snapwell Shipping Container for Live Cell Cultures

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.

This technology includes a specialized container designed for the secure shipping of fragile cell cultures grown on the Snapwell insert system, preventing media splashing that can damage the cells. The problem this invention addresses is the lack of reliable shipping options for sensitive tissues that cannot be frozen, which are increasingly used in tissue transplantation applications. Current methods do not adequately protect these tissues during transport, leading to potential damage and loss of viability.

The technical solution involves a series of thermo-molded inserts placed within standard 50ml containers, which create smaller protective compartments around the living cells. This design minimizes the movement of surrounding media, thereby reducing the risk of damage to the cell layer. This innovation is particularly relevant for academic institutions, biotechnology companies, and military applications, all of which are exploring new tissue transplantation technologies and require dependable shipping solutions.

We are seeking licensing opportunities for this technology, which has the potential for significant impact in the transplantation field. The prototype is ready for testing in research settings, and we are open to collaboration with partners interested in commercializing this invention.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.

This technology includes a specialized container designed for the secure shipping of fragile cell cultures grown on the Snapwell insert system, preventing media splashing that can damage the cells. The problem this invention addresses is the lack of reliable shipping options for sensitive tissues that cannot be frozen, which are increasingly used in tissue transplantation applications. Current methods do not adequately protect these tissues during transport, leading to potential damage and loss of viability.

The technical solution involves a series of thermo-molded inserts placed within standard 50ml containers, which create smaller protective compartments around the living cells. This design minimizes the movement of surrounding media, thereby reducing the risk of damage to the cell layer. This innovation is particularly relevant for academic institutions, biotechnology companies, and military applications, all of which are exploring new tissue transplantation technologies and require dependable shipping solutions.

We are seeking licensing opportunities for this technology, which has the potential for significant impact in the transplantation field. The prototype is ready for testing in research settings, and we are open to collaboration with partners interested in commercializing this invention.

# data[].attributes.field_commercial_applications.value
•	Shipping live cell cultures for research and clinical applications
•	Transporting sensitive tissues for transplantation
•	Use in academic and commercial laboratories focused on cell culture
•	Military applications requiring secure transport of biological materials
•	Development of specialized shipping solutions for biopharmaceutical companies

# data[].attributes.field_commercial_applications.processed
•	Shipping live cell cultures for research and clinical applications
•	Transporting sensitive tissues for transplantation
•	Use in academic and commercial laboratories focused on cell culture
•	Military applications requiring secure transport of biological materials
•	Development of specialized shipping solutions for biopharmaceutical companies

# data[].attributes.field_competitive_advantages.value
•	Provides a simple and cost-effective solution for shipping live cells without freezing
•	Protects fragile cell cultures from damage during transport
•	Customizable insert configurations to fit various container types
•	Utilizes FDA-approved materials for safety and compliance
•	Addresses a critical gap in the market for reliable tissue transportation

# data[].attributes.field_competitive_advantages.processed
•	Provides a simple and cost-effective solution for shipping live cells without freezing
•	Protects fragile cell cultures from damage during transport
•	Customizable insert configurations to fit various container types
•	Utilizes FDA-approved materials for safety and compliance
•	Addresses a critical gap in the market for reliable tissue transportation

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5118] Snapwell Shipping Container for Live Cell Cultures&body=Please send me information about technology [TAB-5118] Snapwell Shipping Container for Live Cell Cultures.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5118] Snapwell Shipping Container for Live Cell Cultures&body=Please send me information about technology [TAB-5118] Snapwell Shipping Container for Live Cell Cultures.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/524,434
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/524,434
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2024/035854
Filed on 2024-06-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2024/035854
Filed on 2024-06-27
Status: Expired

# data[].attributes.field_patents[].value
Canada
National Stage 3297165
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3297165
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2024308721
Filed on 2026-01-06
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2024308721
Filed on 2026-01-06
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 19/498,146
Filed on 2025-12-30
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 19/498,146
Filed on 2025-12-30
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 24746096.7
Filed on 2026-01-14
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 24746096.7
Filed on 2026-01-14
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/524,434
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2024/035854
Filed on 2024-06-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3297165
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2024308721
Filed on 2026-01-06
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 19/498,146
Filed on 2025-12-30
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 24746096.7
Filed on 2026-01-14
Status: Pending

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_technology_names[]
Container for shipping live cells on Snapwell

# data[].attributes.title
Targeted Disruption of Rpe65 Gene for Retinal Disease Research

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.

This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for studying inherited retinal diseases and testing potential therapies. The RPE65 protein is essential for converting dietary vitamin A into the 11-cis isomer, a vital component for vision. The absence of this protein in our mouse model leads to a complete lack of 11-cis retinoids, resulting in blindness, thus confirming its role in the visual cycle. This innovative genetic strategy not only provides insights into the biochemical processes of vision but also opens avenues for developing treatments for RPE65-related retinal disorders.

The technical solution involves creating a genetically modified mouse model that lacks the Rpe65 gene, allowing researchers to observe the resulting phenotype and understand the implications of RPE65 mutations in human diseases. This model is particularly valuable for pharmaceutical companies and research institutions focused on ocular health, as it enables the testing of new drugs and therapies aimed at restoring vision in patients with RPE65 mutations. By utilizing this model, stakeholders can accelerate the development of effective treatments for retinal diseases, ultimately benefiting patients suffering from vision loss.

We are seeking licensing opportunities for this groundbreaking technology, which has already garnered interest from companies such as Acucela Inc. Collaborators can expect a mutually beneficial partnership that leverages our expertise in genetic engineering and retinal biology to advance therapeutic solutions. Licensing this technology will provide access to a unique research tool that can significantly impact the field of ophthalmology and vision science.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.

This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for studying inherited retinal diseases and testing potential therapies. The RPE65 protein is essential for converting dietary vitamin A into the 11-cis isomer, a vital component for vision. The absence of this protein in our mouse model leads to a complete lack of 11-cis retinoids, resulting in blindness, thus confirming its role in the visual cycle. This innovative genetic strategy not only provides insights into the biochemical processes of vision but also opens avenues for developing treatments for RPE65-related retinal disorders.

The technical solution involves creating a genetically modified mouse model that lacks the Rpe65 gene, allowing researchers to observe the resulting phenotype and understand the implications of RPE65 mutations in human diseases. This model is particularly valuable for pharmaceutical companies and research institutions focused on ocular health, as it enables the testing of new drugs and therapies aimed at restoring vision in patients with RPE65 mutations. By utilizing this model, stakeholders can accelerate the development of effective treatments for retinal diseases, ultimately benefiting patients suffering from vision loss.

We are seeking licensing opportunities for this groundbreaking technology, which has already garnered interest from companies such as Acucela Inc. Collaborators can expect a mutually beneficial partnership that leverages our expertise in genetic engineering and retinal biology to advance therapeutic solutions. Licensing this technology will provide access to a unique research tool that can significantly impact the field of ophthalmology and vision science.

# data[].attributes.field_commercial_applications.value
•	Research into inherited retinal diseases
•	Testing of therapeutic compounds for RPE65 mutations
•	Development of gene therapies for vision restoration
•	Pharmaceutical research and development
•	Ocular health diagnostics and treatments

# data[].attributes.field_commercial_applications.processed
•	Research into inherited retinal diseases
•	Testing of therapeutic compounds for RPE65 mutations
•	Development of gene therapies for vision restoration
•	Pharmaceutical research and development
•	Ocular health diagnostics and treatments

# data[].attributes.field_competitive_advantages.value
•	First targeted disruption of the RPE65 gene
•	Provides a novel model for studying retinal diseases
•	Facilitates drug testing for RPE65-associated conditions
•	Offers insights into the visual cycle and vitamin A metabolism
•	Potential for collaboration with industry leaders

# data[].attributes.field_competitive_advantages.processed
•	First targeted disruption of the RPE65 gene
•	Provides a novel model for studying retinal diseases
•	Facilitates drug testing for RPE65-associated conditions
•	Offers insights into the visual cycle and vitamin A metabolism
•	Potential for collaboration with industry leaders

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research&body=Please send me information about technology [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research&body=Please send me information about technology [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_publications[].value
Redmond, T.M., et al., 1998 (PMID: 9843205)

# data[].attributes.field_publications[].processed
Redmond, T.M., et al., 1998 (PMID: 9843205)

# data[].attributes.field_technology_names[]
Targeted Disruption Of Rpe65 Gene In Mouse

# data[].attributes.title
Detection of Organomercurial Compound Biosynthesis in Microbial Communities

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.

This technology includes a novel method for detecting organomercurial compound biosynthesis, which poses significant health risks due to mercury contamination. Current detection methods primarily focus on the HgcAB system, which is limited in scope and effectiveness. Our approach leverages sequence-based techniques to identify a new family of radical SAM proteins that are likely involved in the formation of organomercurials through an unknown mechanism. This advancement allows for a more comprehensive and accurate identification of mercury-methylating organisms, which is crucial for assessing environmental and health risks.

The technical solution involves the construction of a hidden Markov model (HMM) named NF040546, which serves as a search tool to identify members of this novel enzyme family. This is important because it opens new avenues for understanding microbial mercury methylation pathways, which have been inadequately characterized by existing methods. By improving detection capabilities, this technology can significantly enhance environmental monitoring and public health safety, making it a valuable asset for researchers and industries concerned with mercury contamination.

We are seeking licensing opportunities for this technology, which has the potential to be developed into commercial products or services aimed at environmental monitoring and health risk assessment. Collaborators or licensees can expect to engage in a mutually beneficial partnership that leverages our innovative detection methods and their applications in various fields, including agriculture and public health.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.

This technology includes a novel method for detecting organomercurial compound biosynthesis, which poses significant health risks due to mercury contamination. Current detection methods primarily focus on the HgcAB system, which is limited in scope and effectiveness. Our approach leverages sequence-based techniques to identify a new family of radical SAM proteins that are likely involved in the formation of organomercurials through an unknown mechanism. This advancement allows for a more comprehensive and accurate identification of mercury-methylating organisms, which is crucial for assessing environmental and health risks.

The technical solution involves the construction of a hidden Markov model (HMM) named NF040546, which serves as a search tool to identify members of this novel enzyme family. This is important because it opens new avenues for understanding microbial mercury methylation pathways, which have been inadequately characterized by existing methods. By improving detection capabilities, this technology can significantly enhance environmental monitoring and public health safety, making it a valuable asset for researchers and industries concerned with mercury contamination.

We are seeking licensing opportunities for this technology, which has the potential to be developed into commercial products or services aimed at environmental monitoring and health risk assessment. Collaborators or licensees can expect to engage in a mutually beneficial partnership that leverages our innovative detection methods and their applications in various fields, including agriculture and public health.

# data[].attributes.field_commercial_applications.value
•	Sequencing and analysis methods for detecting mercury-methylated microbes in agricultural and human microbiomes
•	Development of probiotic microbes or prebiotic supplements to reduce mercury-methylating microbes in human gut microbiomes
•	Environmental monitoring tools for assessing mercury contamination risks in various ecosystems

# data[].attributes.field_commercial_applications.processed
•	Sequencing and analysis methods for detecting mercury-methylated microbes in agricultural and human microbiomes
•	Development of probiotic microbes or prebiotic supplements to reduce mercury-methylating microbes in human gut microbiomes
•	Environmental monitoring tools for assessing mercury contamination risks in various ecosystems

# data[].attributes.field_competitive_advantages.value
•	Novel detection method for organomercurial biosynthesis that surpasses existing technologies
•	Utilizes sequence-based methods to identify previously uncharacterized microbial pathways
•	Enhances accuracy and thoroughness in identifying mercury-methylating organisms
•	Potential for broad applications in environmental monitoring and public health safety

# data[].attributes.field_competitive_advantages.processed
•	Novel detection method for organomercurial biosynthesis that surpasses existing technologies
•	Utilizes sequence-based methods to identify previously uncharacterized microbial pathways
•	Enhances accuracy and thoroughness in identifying mercury-methylating organisms
•	Potential for broad applications in environmental monitoring and public health safety

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/642,512
Filed on 2024-05-03
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/642,512
Filed on 2024-05-03
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/027781
Filed on 2025-05-05
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/027781
Filed on 2025-05-05
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/642,512
Filed on 2024-05-03
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/027781
Filed on 2025-05-05
Status: Pending

# data[].attributes.field_patent_titles[]
CORYNEBACTERIUM MASTITIDIS-DERIVED MYCOLATES FOR TREATING OCULAR SURFACE DISEASES

# data[].attributes.field_publications[].value
Xiaoyan Xu, et al., 2026 (PMID 41558487)

# data[].attributes.field_publications[].processed
Xiaoyan Xu, et al., 2026 (PMID 41558487)

# data[].attributes.field_technology_names[]
Corynebacterium mastitidis-derived mycolates for treating ocular surface diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.

This technology includes a dual-layer biodegradable tissue scaffold designed for the transplantation of multiple tissue types, such as retinal pigment epithelium (RPE) and photoreceptors. The current challenge in tissue transplantation is the lack of mechanical strength in existing scaffolds, which often leads to separation during handling and implantation. This innovative scaffold addresses these issues by utilizing a unique structure made from poly(lactic-co-glycolic acid) (PLGA) that combines a lower support layer with a secondary matrix of lactide-rich loops, enhancing stability and facilitating cell adhesion and polarization.

The technical solution involves a temperature-fused design that creates a robust scaffold with minimal capillary forces, allowing for better integration of the two tissue layers. This is particularly important for complex eye surgeries where multiple tissues are affected. By providing a supportive environment for weakly adherent cells, this scaffold can significantly improve the outcomes of retinal and choroidal transplants, making it a valuable tool for restoring vision in patients with advanced eye diseases.

The licensing opportunity for this technology is open for collaboration with industry partners interested in advancing tissue engineering and transplantation techniques. The inventor seeks partnerships that can help bring this innovative scaffold to market, focusing on its application in regenerative medicine and ophthalmology.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.

This technology includes a dual-layer biodegradable tissue scaffold designed for the transplantation of multiple tissue types, such as retinal pigment epithelium (RPE) and photoreceptors. The current challenge in tissue transplantation is the lack of mechanical strength in existing scaffolds, which often leads to separation during handling and implantation. This innovative scaffold addresses these issues by utilizing a unique structure made from poly(lactic-co-glycolic acid) (PLGA) that combines a lower support layer with a secondary matrix of lactide-rich loops, enhancing stability and facilitating cell adhesion and polarization.

The technical solution involves a temperature-fused design that creates a robust scaffold with minimal capillary forces, allowing for better integration of the two tissue layers. This is particularly important for complex eye surgeries where multiple tissues are affected. By providing a supportive environment for weakly adherent cells, this scaffold can significantly improve the outcomes of retinal and choroidal transplants, making it a valuable tool for restoring vision in patients with advanced eye diseases.

The licensing opportunity for this technology is open for collaboration with industry partners interested in advancing tissue engineering and transplantation techniques. The inventor seeks partnerships that can help bring this innovative scaffold to market, focusing on its application in regenerative medicine and ophthalmology.

# data[].attributes.field_commercial_applications.value
•	Retinal and choroidal tissue transplantation
•	Regenerative medicine for ocular diseases
•	Development of multi-tissue implants for complex surgical procedures
•	Research applications in tissue engineering and biomaterials
•	Potential use in other organ systems requiring scaffold support

# data[].attributes.field_commercial_applications.processed
•	Retinal and choroidal tissue transplantation
•	Regenerative medicine for ocular diseases
•	Development of multi-tissue implants for complex surgical procedures
•	Research applications in tissue engineering and biomaterials
•	Potential use in other organ systems requiring scaffold support

# data[].attributes.field_competitive_advantages.value
•	Biodegradable material ensures anatomical integrity post-transplant
•	Enhanced mechanical strength through fused fibers and loop structures
•	Reduced capillary forces improve cell integration and function
•	Facilitates the transplantation of multiple tissue types simultaneously
•	Customizable for various tissue engineering applications

# data[].attributes.field_competitive_advantages.processed
•	Biodegradable material ensures anatomical integrity post-transplant
•	Enhanced mechanical strength through fused fibers and loop structures
•	Reduced capillary forces improve cell integration and function
•	Facilitates the transplantation of multiple tissue types simultaneously
•	Customizable for various tissue engineering applications

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/194,770
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/194,770
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/031107
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/031107
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2023-572792
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2023-572792
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3220433
Filed on 2023-11-15
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3220433
Filed on 2023-11-15
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2022282379
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2022282379
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/290,396
Filed on 2023-11-13
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/290,396
Filed on 2023-11-13
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Spain
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Spain
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Italy
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Italy
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Denmark
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Denmark
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Belgium
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Belgium
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Sweden
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Sweden
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Switzerland
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Switzerland
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
The Netherlands
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
The Netherlands
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/194,770
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/031107
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2023-572792
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3220433
Filed on 2023-11-15
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2022282379
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/290,396
Filed on 2023-11-13
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Spain
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Italy
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Denmark
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Belgium
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Sweden
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Switzerland
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
The Netherlands
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_technology_names[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.title
A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.

This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells, which are crucial for developing targeted cell therapies and drug discovery for retinal degenerative diseases. The problem lies in the lack of in vitro models that accurately reproduce the regional diversity and vulnerability of RPE cells, particularly in conditions like age-related macular degeneration (AMD) and retinitis pigmentosa. Our innovative approach utilizes two specific drugs, AGN 193109 and endo-IWR 1, to induce distinct macular and peripheral RPE phenotypes from induced pluripotent stem cells (iPSCs), enabling the study of regional RPE defects and high-throughput drug screening for specific retinal conditions.

The technical solution leverages the unique properties of iPSC-derived RPE cells, which can be manipulated to reflect the diverse characteristics of human RPE. This is significant because it allows researchers and clinicians to better understand the mechanisms underlying retinal diseases and to develop targeted therapies. By creating a high-throughput platform for generating various RPE cell types, we can facilitate the discovery of disease-specific pathways and drug candidates, ultimately leading to improved treatment options for patients suffering from retinal degenerative diseases.

We are seeking licensing opportunities for this technology, which has the potential to revolutionize the field of retinal research and therapy. Collaborators and licensees will benefit from access to a cutting-edge platform that addresses a critical gap in current RPE research and therapeutic development. We are open to discussions regarding potential partnerships and collaborations to further advance this technology.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.

This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells, which are crucial for developing targeted cell therapies and drug discovery for retinal degenerative diseases. The problem lies in the lack of in vitro models that accurately reproduce the regional diversity and vulnerability of RPE cells, particularly in conditions like age-related macular degeneration (AMD) and retinitis pigmentosa. Our innovative approach utilizes two specific drugs, AGN 193109 and endo-IWR 1, to induce distinct macular and peripheral RPE phenotypes from induced pluripotent stem cells (iPSCs), enabling the study of regional RPE defects and high-throughput drug screening for specific retinal conditions.

The technical solution leverages the unique properties of iPSC-derived RPE cells, which can be manipulated to reflect the diverse characteristics of human RPE. This is significant because it allows researchers and clinicians to better understand the mechanisms underlying retinal diseases and to develop targeted therapies. By creating a high-throughput platform for generating various RPE cell types, we can facilitate the discovery of disease-specific pathways and drug candidates, ultimately leading to improved treatment options for patients suffering from retinal degenerative diseases.

We are seeking licensing opportunities for this technology, which has the potential to revolutionize the field of retinal research and therapy. Collaborators and licensees will benefit from access to a cutting-edge platform that addresses a critical gap in current RPE research and therapeutic development. We are open to discussions regarding potential partnerships and collaborations to further advance this technology.

# data[].attributes.field_commercial_applications.value
•	Development of macular and peripheral RPE patches for cell therapy
•	High-throughput drug screening for retinal diseases
•	In vitro modeling of retinal degenerative diseases
•	Research on regional RPE defects in various conditions
•	Discovery of disease-specific pathways and drug candidates

# data[].attributes.field_commercial_applications.processed
•	Development of macular and peripheral RPE patches for cell therapy
•	High-throughput drug screening for retinal diseases
•	In vitro modeling of retinal degenerative diseases
•	Research on regional RPE defects in various conditions
•	Discovery of disease-specific pathways and drug candidates

# data[].attributes.field_competitive_advantages.value
•	Unique ability to generate macular and peripheral RPE cells in vitro
•	Addresses a significant gap in current retinal research models
•	Enables high-throughput drug screening for specific retinal diseases
•	Provides a platform for studying regional RPE defects and disease mechanisms
•	Potential for developing targeted cell therapies for retinal degenerative diseases

# data[].attributes.field_competitive_advantages.processed
•	Unique ability to generate macular and peripheral RPE cells in vitro
•	Addresses a significant gap in current retinal research models
•	Enables high-throughput drug screening for specific retinal diseases
•	Provides a platform for studying regional RPE defects and disease mechanisms
•	Potential for developing targeted cell therapies for retinal degenerative diseases

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/194,774
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/194,774
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/031136
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/031136
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2023-572794
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2023-572794
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3220602
Filed on 2023-11-17
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3220602
Filed on 2023-11-17
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 22736412.2
Filed on 2023-12-19
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 22736412.2
Filed on 2023-12-19
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2022280062
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2022280062
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/562,806
Filed on 2023-11-20
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/562,806
Filed on 2023-11-20
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/194,774
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/031136
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2023-572794
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3220602
Filed on 2023-11-17
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 22736412.2
Filed on 2023-12-19
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2022280062
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/562,806
Filed on 2023-11-20
Status: Pending

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_publications[].value
Ortolan D, et al., 2022 (PMID: 35522714)

# data[].attributes.field_publications[].processed
Ortolan D, et al., 2022 (PMID: 35522714)

# data[].attributes.field_technology_names[]
A Robust Method To Generate Macular Vs Peripheral RPE Cells Of Cell Therapy And Drug Discovery

# data[].attributes.title
Mini-Bioreactor for Enhanced Organoid Culture

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.

This technology includes a mini-bioreactor designed to improve organoid outcomes in cell culture applications. The bioreactor system is a multi-well, 3D-printed device that fits standard 100 mm cell culture dishes and utilizes a central stirring mechanism to create a controlled laminar flow. This innovative design addresses the common challenges in organoid culture, such as non-specific adherence and fusion, while enhancing mass transfer without the shear stress typically associated with other bioreactor systems.

The technical solution provided by this bioreactor is significant because it simplifies the organoid culture process by integrating a single-component system that is compatible with standard lab equipment. This means that researchers can easily adopt this technology without needing specialized training or additional components. The ability to track individual organoids longitudinally further enhances its utility in research settings, making it an attractive option for laboratories focused on organoid studies.

The licensing opportunity for this technology is promising, as it can be developed and produced in less than two years. Companies that manufacture cell culture vessels, such as Corning, Thermo Fisher, and VWR, may find this bioreactor particularly appealing for their product lines. Collaboration with the inventors is encouraged to explore the full commercial potential of this innovative bioreactor system.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.

This technology includes a mini-bioreactor designed to improve organoid outcomes in cell culture applications. The bioreactor system is a multi-well, 3D-printed device that fits standard 100 mm cell culture dishes and utilizes a central stirring mechanism to create a controlled laminar flow. This innovative design addresses the common challenges in organoid culture, such as non-specific adherence and fusion, while enhancing mass transfer without the shear stress typically associated with other bioreactor systems.

The technical solution provided by this bioreactor is significant because it simplifies the organoid culture process by integrating a single-component system that is compatible with standard lab equipment. This means that researchers can easily adopt this technology without needing specialized training or additional components. The ability to track individual organoids longitudinally further enhances its utility in research settings, making it an attractive option for laboratories focused on organoid studies.

The licensing opportunity for this technology is promising, as it can be developed and produced in less than two years. Companies that manufacture cell culture vessels, such as Corning, Thermo Fisher, and VWR, may find this bioreactor particularly appealing for their product lines. Collaboration with the inventors is encouraged to explore the full commercial potential of this innovative bioreactor system.

# data[].attributes.field_commercial_applications.value
•	Organoid culture for drug testing and development
•	Research in regenerative medicine and tissue engineering
•	Applications in personalized medicine and disease modeling
•	Use in academic and industrial research laboratories

# data[].attributes.field_commercial_applications.processed
•	Organoid culture for drug testing and development
•	Research in regenerative medicine and tissue engineering
•	Applications in personalized medicine and disease modeling
•	Use in academic and industrial research laboratories

# data[].attributes.field_competitive_advantages.value
•	Simplified design with a single component, reducing complexity in organoid culture
•	Compatible with standard 100 mm cell culture dishes and existing lab equipment
•	Enhanced mass transfer without the shear stress associated with traditional bioreactors
•	Longitudinal tracking of individual organoids for improved research outcomes
•	Potential for rapid commercialization within two years

# data[].attributes.field_competitive_advantages.processed
•	Simplified design with a single component, reducing complexity in organoid culture
•	Compatible with standard 100 mm cell culture dishes and existing lab equipment
•	Enhanced mass transfer without the shear stress associated with traditional bioreactors
•	Longitudinal tracking of individual organoids for improved research outcomes
•	Potential for rapid commercialization within two years

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/541,656
Filed on 2023-09-29
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/541,656
Filed on 2023-09-29
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2024/049060
Filed on 2024-09-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2024/049060
Filed on 2024-09-27
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2026-519253
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2026-519253
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2024353162
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2024353162
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 19/524,229
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 19/524,229
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 24790765.2
Filed on 2026-04-29
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 24790765.2
Filed on 2026-04-29
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3305823
Filed on 2026-03-23
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3305823
Filed on 2026-03-23
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/541,656
Filed on 2023-09-29
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2024/049060
Filed on 2024-09-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2026-519253
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2024353162
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 19/524,229
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 24790765.2
Filed on 2026-04-29
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3305823
Filed on 2026-03-23
Status: Pending

# data[].attributes.field_technology_names[]
Mini-bioreactor to improve organoid outcomes

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), National Eye Institute (NEI)

# data[].attributes.title
RPGR Gene Therapy for Retinitis Pigmentosa

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.

This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. The current version of RPGR is known to be unstable and can undergo changes in vivo, which may be harmful to recipient cells. The abbreviated RPGR retains its function, rescues the disease, and is stabilized, making it a safer option for gene therapy.

The technical solution involves using an adeno-associated viral vector that carries the abbreviated human RPGR cDNA. This vector supplies functional RPGR proteins to treat inherited ocular disorders related to RPGR mutations. This technology is significant because it addresses the instability issues of the current RPGR gene therapy approaches, providing a more reliable and effective treatment option for patients suffering from XLRP. Stakeholders in the ophthalmology and gene therapy fields should care about this innovation as it represents a potential breakthrough in treating a debilitating condition.

The licensing opportunity for this technology is open for collaboration with interested parties who are looking to develop and commercialize this gene therapy. The inventors are seeking partners who can assist in further development and potential market entry, ensuring that this promising therapy reaches those in need.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.

This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. The current version of RPGR is known to be unstable and can undergo changes in vivo, which may be harmful to recipient cells. The abbreviated RPGR retains its function, rescues the disease, and is stabilized, making it a safer option for gene therapy.

The technical solution involves using an adeno-associated viral vector that carries the abbreviated human RPGR cDNA. This vector supplies functional RPGR proteins to treat inherited ocular disorders related to RPGR mutations. This technology is significant because it addresses the instability issues of the current RPGR gene therapy approaches, providing a more reliable and effective treatment option for patients suffering from XLRP. Stakeholders in the ophthalmology and gene therapy fields should care about this innovation as it represents a potential breakthrough in treating a debilitating condition.

The licensing opportunity for this technology is open for collaboration with interested parties who are looking to develop and commercialize this gene therapy. The inventors are seeking partners who can assist in further development and potential market entry, ensuring that this promising therapy reaches those in need.

# data[].attributes.field_commercial_applications.value
•	Treatment for X-linked Retinitis Pigmentosa
•	Gene therapy for other inherited retinal diseases
•	Research applications in gene therapy and ophthalmology

# data[].attributes.field_commercial_applications.processed
•	Treatment for X-linked Retinitis Pigmentosa
•	Gene therapy for other inherited retinal diseases
•	Research applications in gene therapy and ophthalmology

# data[].attributes.field_competitive_advantages.value
•	Abbreviated RPGR gene is more stable than the current version
•	Effective in rescuing photoreceptor function in XLRP models
•	Utilizes a safe adeno-associated viral vector for delivery
•	Potential for broader applications in other RPGR-related ocular disorders

# data[].attributes.field_competitive_advantages.processed
•	Abbreviated RPGR gene is more stable than the current version
•	Effective in rescuing photoreceptor function in XLRP models
•	Utilizes a safe adeno-associated viral vector for delivery
•	Potential for broader applications in other RPGR-related ocular disorders

# data[].attributes.field_inventor_companies[]
Massachusetts Eye & Ear Infirmary (MEEI)

# data[].attributes.field_inventor_companies[]
Massachusetts Eye & Ear Infirmary (MEEI)

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa&body=Please send me information about technology [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa&body=Please send me information about technology [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/028,638
Filed on 2014-07-24
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/028,638
Filed on 2014-07-24
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2015/040866
Filed on 2015-07-17
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2015/040866
Filed on 2015-07-17
Status: Expired

# data[].attributes.field_patents[].value
China
National Stage 201580051512.3
Filed on 2015-07-17
Status: Pending

# data[].attributes.field_patents[].processed
China
National Stage 201580051512.3
Filed on 2015-07-17
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 2991750
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Canada
National Stage 2991750
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
European Patent
National Stage 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Japan
National Stage 2017-525514
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Japan
National Stage 2017-525514
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
US Patent 10,314,924
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,314,924
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
US Patent 11,045,558
Filed on 2019-06-10
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 11,045,558
Filed on 2019-06-10
Status: Issued

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2019-235539
Filed on 2019-12-26
Status: Issued

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2019-235539
Filed on 2019-12-26
Status: Issued

# data[].attributes.field_patents[].value
European Patent
Divisional (DIV) 20199208.8
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
Divisional (DIV) 20199208.8
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Belgium
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Belgium
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Bulgaria
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Bulgaria
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Denmark
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Denmark
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Estonia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Estonia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Spain
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Spain
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Finland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Finland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Iceland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Iceland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Italy
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Italy
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Luxembourg
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Luxembourg
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Latvia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Latvia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
The Netherlands
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
The Netherlands
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Portugal
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Portugal
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Sweden
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Sweden
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Turkey
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Turkey
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Cyprus
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Cyprus
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Greece
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Greece
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Hungary
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Hungary
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Malta
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Malta
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2021-172128
Filed on 2021-10-21
Status: Issued

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2021-172128
Filed on 2021-10-21
Status: Issued

# data[].attributes.field_patents[].value
Hong Kong
European patent (EP) 42021042687.0
Filed on 2021-11-18
Status: Pending

# data[].attributes.field_patents[].processed
Hong Kong
European patent (EP) 42021042687.0
Filed on 2021-11-18
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/028,638
Filed on 2014-07-24
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2015/040866
Filed on 2015-07-17
Status: Expired

# data[].attributes.field_patent_htmls[]
China
National Stage 201580051512.3
Filed on 2015-07-17
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2991750
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2017-525514
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 10,314,924
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 11,045,558
Filed on 2019-06-10
Status: Issued

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2019-235539
Filed on 2019-12-26
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
Divisional (DIV) 20199208.8
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Belgium
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Bulgaria
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Denmark
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Estonia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Spain
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Finland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Iceland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Italy
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Luxembourg
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Latvia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
The Netherlands
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Portugal
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Sweden
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Turkey
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Cyprus
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Greece
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Hungary
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Malta
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2021-172128
Filed on 2021-10-21
Status: Issued

# data[].attributes.field_patent_htmls[]
Hong Kong
European patent (EP) 42021042687.0
Filed on 2021-11-18
Status: Pending

# data[].attributes.field_patent_titles[]
THE RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA

# data[].attributes.field_patent_titles[]
Abbreviated Version Of RPGR Is Effective In Gene Replacement Therapy

# data[].attributes.field_patent_titles[]
RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA

# data[].attributes.field_technology_names[]
Abbreviated Version Of RPGR Is Effective In Gene Replacement Therapy

# data[].attributes.field_technology_owners[]
Massachusetts Eye & Ear Infirmary (MEEI), Medical Research Council, National Eye Institute (NEI), University College London

# data[].attributes.title
AI Based Workflow for Single Cell Analysis

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.

This technology includes SCassist, an innovative open-source R package designed to enhance single-cell RNA sequencing (scRNA-seq) data analysis. The complexity of scRNA-seq workflows often requires extensive expertise, making it challenging for many researchers to fully explore their data. This limitation can hinder scientific discovery and innovation, as researchers may struggle to navigate through the intricate stages of data filtering, normalization, clustering, and interpretation. SCassist addresses these challenges by leveraging large language models (LLMs) to provide intelligent recommendations and interpretations throughout the analysis process, making advanced scRNA-seq analysis accessible to researchers at all levels.

SCassist integrates LLMs into key workflow steps, offering guidance on filtering, normalization, clustering parameters, and insightful interpretations of variable features and principal components. It also performs cell type annotations and provides a system-level view through network representations based on pathway and ontology enrichment analyses. This user-friendly interface allows researchers to incorporate AI-driven insights into their scRNA-seq analysis, ultimately accelerating their workflow and uncovering deeper biological understanding. By democratizing scRNA-seq analysis, SCassist empowers researchers to navigate complexities and make the most of their valuable data.

The National Eye Institute (NEI) is seeking licensing opportunities and collaborative partnerships to further develop and expand the capabilities of SCassist. This technology has the potential to be utilized across various fields, including genomics, proteomics, and metabolomics, enabling researchers to gain novel insights into their ‘omics’ scale data. The NEI welcomes inquiries from potential partners interested in leveraging SCassist to enhance their research capabilities and drive scientific innovation.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.

This technology includes SCassist, an innovative open-source R package designed to enhance single-cell RNA sequencing (scRNA-seq) data analysis. The complexity of scRNA-seq workflows often requires extensive expertise, making it challenging for many researchers to fully explore their data. This limitation can hinder scientific discovery and innovation, as researchers may struggle to navigate through the intricate stages of data filtering, normalization, clustering, and interpretation. SCassist addresses these challenges by leveraging large language models (LLMs) to provide intelligent recommendations and interpretations throughout the analysis process, making advanced scRNA-seq analysis accessible to researchers at all levels.

SCassist integrates LLMs into key workflow steps, offering guidance on filtering, normalization, clustering parameters, and insightful interpretations of variable features and principal components. It also performs cell type annotations and provides a system-level view through network representations based on pathway and ontology enrichment analyses. This user-friendly interface allows researchers to incorporate AI-driven insights into their scRNA-seq analysis, ultimately accelerating their workflow and uncovering deeper biological understanding. By democratizing scRNA-seq analysis, SCassist empowers researchers to navigate complexities and make the most of their valuable data.

The National Eye Institute (NEI) is seeking licensing opportunities and collaborative partnerships to further develop and expand the capabilities of SCassist. This technology has the potential to be utilized across various fields, including genomics, proteomics, and metabolomics, enabling researchers to gain novel insights into their ‘omics’ scale data. The NEI welcomes inquiries from potential partners interested in leveraging SCassist to enhance their research capabilities and drive scientific innovation.

# data[].attributes.field_commercial_applications.value
•	Basic researchers
•	Biomarker identification, toxicology studies, cell therapy development
•	Companies specializing in single cell sequencing technologies can incorporate SCassist into their product offerings, enhancing the analytical capabilities and value of their platforms
•	Companies providing sequencing services can integrate an analysis platform for customers

# data[].attributes.field_commercial_applications.processed
•	Basic researchers
•	Biomarker identification, toxicology studies, cell therapy development
•	Companies specializing in single cell sequencing technologies can incorporate SCassist into their product offerings, enhancing the analytical capabilities and value of their platforms
•	Companies providing sequencing services can integrate an analysis platform for customers

# data[].attributes.field_competitive_advantages.value
•	Makes scRNA-seq analysis accessible to researchers at all levels by providing user guidance in a user-friendly interface
•	Incorporation of artificial intelligence assistance for parameter selections
•	Seamlessly integrates LLMs into the standard single cell analysis workflow, providing LLM-guided interpretations, cell type annotations, and enrichment analysis
•	Addresses the computational challenges associated with single-cell RNA-seq data analysis, regardless of how libraries and data are generated
•	All encompassing workflow from start to finish

# data[].attributes.field_competitive_advantages.processed
•	Makes scRNA-seq analysis accessible to researchers at all levels by providing user guidance in a user-friendly interface
•	Incorporation of artificial intelligence assistance for parameter selections
•	Seamlessly integrates LLMs into the standard single cell analysis workflow, providing LLM-guided interpretations, cell type annotations, and enrichment analysis
•	Addresses the computational challenges associated with single-cell RNA-seq data analysis, regardless of how libraries and data are generated
•	All encompassing workflow from start to finish

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5104] AI Based Workflow for Single Cell Analysis&body=Please send me information about technology [TAB-5104] AI Based Workflow for Single Cell Analysis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5104] AI Based Workflow for Single Cell Analysis&body=Please send me information about technology [TAB-5104] AI Based Workflow for Single Cell Analysis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/739,320
Filed on 2024-12-27
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/739,320
Filed on 2024-12-27
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/061495
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/061495
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/739,320
Filed on 2024-12-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/061495
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE BASED WORKFLOW ASSISTANT FOR SINGLE CELL ANALYSIS

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE BASED WORKFLOW ASSISTANT FOR SINGLE CELL ANALYSIS

# data[].attributes.field_publications[].value
Nagarajan V, et al., 2005 (PMID 40093069)

# data[].attributes.field_publications[].processed
Nagarajan V, et al., 2005 (PMID 40093069)

# data[].attributes.field_technology_names[]
AI Based Workflow Assistant for Single Cell Analysis

# data[].attributes.title
EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

# data[].attributes.body.value
Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have identified four monoclonal antibodies that potently bind and neutralize multiple subclades of EV-D68, including B3 and A2 variants. Animal studies have indicated that these Rhesus macaque-derived monoclonal antibodies (mAbs) are likely to confer protection against respiratory illness in young children (particularly those under age 5) and in individuals with respiratory or immunocompromising conditions. Analyses conducted using standard techniques such as cryo-EM have enabled the inventors to further characterize the epitopes of two unique EV-D68-specific antibodies, suggesting the value of this technology for developing multi-specific approaches that confer broad protection against EV-D68.

Humanization and combination of these mAbs with other antibodies exhibiting unique epitope specificities may prove beneficial for therapeutic or prophylactic purposes, especially within the context of a broader pandemic preparedness program. Further, these antibodies could be incorporated into diagnostic assays/kits for the rapid and accurate detection of EV-D68 in clinical or non-clinical settings.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

# data[].attributes.body.processed
Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have identified four monoclonal antibodies that potently bind and neutralize multiple subclades of EV-D68, including B3 and A2 variants. Animal studies have indicated that these Rhesus macaque-derived monoclonal antibodies (mAbs) are likely to confer protection against respiratory illness in young children (particularly those under age 5) and in individuals with respiratory or immunocompromising conditions. Analyses conducted using standard techniques such as cryo-EM have enabled the inventors to further characterize the epitopes of two unique EV-D68-specific antibodies, suggesting the value of this technology for developing multi-specific approaches that confer broad protection against EV-D68.

Humanization and combination of these mAbs with other antibodies exhibiting unique epitope specificities may prove beneficial for therapeutic or prophylactic purposes, especially within the context of a broader pandemic preparedness program. Further, these antibodies could be incorporated into diagnostic assays/kits for the rapid and accurate detection of EV-D68 in clinical or non-clinical settings.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

# data[].attributes.field_commercial_applications.value
Prevention or treatment of EV-D68 infection

Development of diagnostic assays for rapid, accurate EV-D68 detection in clinical and non-clinical settings

# data[].attributes.field_commercial_applications.processed
Prevention or treatment of EV-D68 infection

Development of diagnostic assays for rapid, accurate EV-D68 detection in clinical and non-clinical settings

# data[].attributes.field_competitive_advantages.value
Development of prophylactic or therapeutic interventions against EV-D68 that effectively induce broad protection against multiple circulating subclades

# data[].attributes.field_competitive_advantages.processed
Development of prophylactic or therapeutic interventions against EV-D68 that effectively induce broad protection against multiple circulating subclades

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques.

# data[].attributes.field_licensingcontact_htmls[]
Bailey, Brian
bbailey@mail.nih.gov

# data[].attributes.field_licensing_contacts[].value
Bailey, Brian
bbailey@mail.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Bailey, Brian
bbailey@mail.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/640,619
Filed on 2024-04-30
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/640,619
Filed on 2024-04-30
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/027110
Filed on 2025-04-30
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/027110
Filed on 2025-04-30
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/640,619
Filed on 2024-04-30
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/027110
Filed on 2025-04-30
Status: Pending

# data[].attributes.field_publications[].value
Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076

# data[].attributes.field_publications[].processed
Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076

# data[].attributes.field_technology_names[]
EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIH - NIAID

# data[].attributes.title
Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration

# data[].attributes.body.value
Summary:

The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.

Description of Technology:

Inherited Retinal Degenerations (IRD), such as Leber Congenital Amaurosis (LCA) and retinitis pigmentosa (RP), are characterized by a progressive loss of photo-sensitive cells in the retina. Most forms of IRD have no therapeutic options available due to their genetic heterogeneity and/or lack of mechanistic understanding. In particular, LCA represents roughly 5% of all retinal dystrophies and results in severe vision loss at an early age. There is an FDA-approved treatment for one form of LCA caused by mutations in the RPE 65 gene. This involves injection of an adenovirus vector containing the normal copy of the RPE65 gene. Long-term data for the gene therapy achieved only transient results: progressive reduction in visual acuity, sensitivity and function occurred following an initial gain seen 6-12 months post-treatment.

RP is a collection of rare eye diseases that affect roughly 1 in 4000 people worldwide. Currently, as there are no treatments, a majority of affected individuals lose most of their sight.

By 2040, age-related macular degeneration (AMD) will affect ~288 million people worldwide. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.

Scientists at the National Eye Institute (NEI) have developed a mutation-independent method to treat LCA, RP, other IRDs, and AMD using the FDA-approved small molecule, Halofantrine (NCGC00016833-01). Halofantrine, which was previously approved to treat malaria, helped protect photoreceptors from cell death in three different IRD model systems in 1) retinal organoid model systems, 2) two different mouse models, and 3) rat models. Furthermore, packaging Halofantrine and other potential candidate compounds for conjunctival delivery into the eye via eye drops is under development.

These small molecules act by targeting several cellular pathways which are also affected in diseases of other organs, suggesting that they may be useful in treating other, mutation independent ocular diseases.

Potential Commercial Applications:

Therapeutic to treat Leber congenital amaurosis

Therapeutic to treat Inherited Retinal Disorders associated with photoreceptor degeneration

Therapeutic to treat AMD

Therapeutic to treat mutation-independent ocular diseases

Competitive Advantages:

Less time-consuming, costly and labor intensive versus the development of individualized gene therapies

Small molecules are scalable with cost-effective manufacturing

Small molecules are highly penetrant with easy routes of administration

Small molecules can be delivered via eye drops or as intra-vitreal injection

Less intrusive and easy administration route

Conjunctival delivery and eye drop formulation more accessible than retinal implant or injection

# data[].attributes.body.processed
Summary:

The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.

Description of Technology:

Inherited Retinal Degenerations (IRD), such as Leber Congenital Amaurosis (LCA) and retinitis pigmentosa (RP), are characterized by a progressive loss of photo-sensitive cells in the retina. Most forms of IRD have no therapeutic options available due to their genetic heterogeneity and/or lack of mechanistic understanding. In particular, LCA represents roughly 5% of all retinal dystrophies and results in severe vision loss at an early age. There is an FDA-approved treatment for one form of LCA caused by mutations in the RPE 65 gene. This involves injection of an adenovirus vector containing the normal copy of the RPE65 gene. Long-term data for the gene therapy achieved only transient results: progressive reduction in visual acuity, sensitivity and function occurred following an initial gain seen 6-12 months post-treatment.

RP is a collection of rare eye diseases that affect roughly 1 in 4000 people worldwide. Currently, as there are no treatments, a majority of affected individuals lose most of their sight.

By 2040, age-related macular degeneration (AMD) will affect ~288 million people worldwide. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.

Scientists at the National Eye Institute (NEI) have developed a mutation-independent method to treat LCA, RP, other IRDs, and AMD using the FDA-approved small molecule, Halofantrine (NCGC00016833-01). Halofantrine, which was previously approved to treat malaria, helped protect photoreceptors from cell death in three different IRD model systems in 1) retinal organoid model systems, 2) two different mouse models, and 3) rat models. Furthermore, packaging Halofantrine and other potential candidate compounds for conjunctival delivery into the eye via eye drops is under development.

These small molecules act by targeting several cellular pathways which are also affected in diseases of other organs, suggesting that they may be useful in treating other, mutation independent ocular diseases.

Potential Commercial Applications:

Therapeutic to treat Leber congenital amaurosis

Therapeutic to treat Inherited Retinal Disorders associated with photoreceptor degeneration

Therapeutic to treat AMD

Therapeutic to treat mutation-independent ocular diseases

Competitive Advantages:

Less time-consuming, costly and labor intensive versus the development of individualized gene therapies

Small molecules are scalable with cost-effective manufacturing

Small molecules are highly penetrant with easy routes of administration

Small molecules can be delivered via eye drops or as intra-vitreal injection

Less intrusive and easy administration route

Conjunctival delivery and eye drop formulation more accessible than retinal implant or injection

# data[].attributes.field_collaboration_description.value
Researchers at the NEI seek licensing and/or co-development research collaborations  for a therapy using an FDA-approved small molecule drug reserpine and related compounds (such as halofantrine) that prevents retinal degeneration.

# data[].attributes.field_collaboration_description.processed
Researchers at the NEI seek licensing and/or co-development research collaborations  for a therapy using an FDA-approved small molecule drug reserpine and related compounds (such as halofantrine) that prevents retinal degeneration.

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/047,858
Filed on 2020-07-02
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/047,858
Filed on 2020-07-02
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/040157
Filed on 2021-07-01
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/040157
Filed on 2021-07-01
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2021300425
Filed on 2022-12-08
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2021300425
Filed on 2022-12-08
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3186586
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3186586
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 21751672.3
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 21751672.3
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].value
Japan
National Stage 2022-581456
Filed on 2022-12-28
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2022-581456
Filed on 2022-12-28
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/014,045
Filed on 2022-12-30
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/014,045
Filed on 2022-12-30
Status: Pending

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2026-019246
Filed on 2026-02-09
Status: Pending

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2026-019246
Filed on 2026-02-09
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/047,858
Filed on 2020-07-02
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/040157
Filed on 2021-07-01
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2021300425
Filed on 2022-12-08
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3186586
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 21751672.3
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2022-581456
Filed on 2022-12-28
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/014,045
Filed on 2022-12-30
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2026-019246
Filed on 2026-02-09
Status: Pending

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_publications[].value
Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211)

# data[].attributes.field_publications[].processed
Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211)

# data[].attributes.field_technology_names[]
Small Molecule Drug Candidates And Disease-associated Signature Genes For Therapeutic Interventions In Retinal Degeneration

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), NCATS - NCGC

# data[].attributes.title
First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)

# data[].attributes.body.value
It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.

The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this disclosure possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.

NCATS in collaboration with Florida International University (FIU) and University of South Florida (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous cancers, fibrotic, and vascular disorders.

NCATS is actively seeking licensing to develop therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast cancer, solid tumors, atherosclerosis, and liver fibrosis.

# data[].attributes.body.processed
It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.

The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this disclosure possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.

NCATS in collaboration with Florida International University (FIU) and University of South Florida (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous cancers, fibrotic, and vascular disorders.

NCATS is actively seeking licensing to develop therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast cancer, solid tumors, atherosclerosis, and liver fibrosis.

# data[].attributes.field_collaboration_description.value
Researchers at the National Center for Advancing Translational Sciences (NCATS) seek to license these molecules.

Licensing Contact: 
Jasmine Kalsi, M.S.
Email: jasmine.kalsi@nih.gov
Telephone: 301.435.0129

# data[].attributes.field_collaboration_description.processed
Researchers at the National Center for Advancing Translational Sciences (NCATS) seek to license these molecules.

Licensing Contact: 
Jasmine Kalsi, M.S.
Email: jasmine.kalsi@nih.gov
Telephone: 301.435.0129

# data[].attributes.field_commercial_applications.value
Vascular health

Fibrotic diseases

Cancers

Human reproductive health

# data[].attributes.field_commercial_applications.processed
Vascular health

Fibrotic diseases

Cancers

Human reproductive health

# data[].attributes.field_competitive_advantages.value
First and only small molecule agonists of RXFP1

Potent and highly selective

Bioavailable with excellent exposure

Easy to synthesize and scale-up

# data[].attributes.field_competitive_advantages.processed
First and only small molecule agonists of RXFP1

Potent and highly selective

Bioavailable with excellent exposure

Easy to synthesize and scale-up

# data[].attributes.field_inventor_companies[]
National Center for Advancing Translational Sciences

# data[].attributes.field_inventor_companies[]
National Center for Advancing Translational Sciences

# data[].attributes.field_licensingcontact_hrefs[]
jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02).

# data[].attributes.field_licensingcontact_htmls[]
Kalsi, Jasmine
jasmine.kalsi@nih.gov

# data[].attributes.field_licensing_contacts[].value
Kalsi, Jasmine
jasmine.kalsi@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Kalsi, Jasmine
jasmine.kalsi@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02).

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/757,235
Filed on 2025-02-11
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/757,235
Filed on 2025-02-11
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/780,976
Filed on 2025-03-31
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/780,976
Filed on 2025-03-31
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2026/021648
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2026/021648
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/757,235
Filed on 2025-02-11
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/780,976
Filed on 2025-03-31
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2026/021648
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_technology_names[]
NCGC00846044 is a novel functionally selective RXFP1 agonist with exceptional properties

# data[].attributes.field_technology_owners[]
Florida International University (FIU), National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, NCATS - NCGC, NCATS - NCGC, NCATS - TRND, University of South Florida

# data[].attributes.title
48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio

# data[].attributes.body.value
CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of the microplate has been shown to reduce errors, while increasing accuracy, precision, and sensitivity.

Thus far, the microplate has been successfully used for free testosterone measurement. The microplate may also be used for measuring other analytes and has the potential to be used in both clinical and research settings.

# data[].attributes.body.processed
CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of the microplate has been shown to reduce errors, while increasing accuracy, precision, and sensitivity.

Thus far, the microplate has been successfully used for free testosterone measurement. The microplate may also be used for measuring other analytes and has the potential to be used in both clinical and research settings.

# data[].attributes.field_collaboration_description.value
The CDC-NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the multi-well dialysis microplate. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov; TTO@cdc.gov.

# data[].attributes.field_collaboration_description.processed
The CDC-NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the multi-well dialysis microplate. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov; TTO@cdc.gov.

# data[].attributes.field_commercial_applications.value
Diagnostics: Meets the criteria of American National Standards Institute (ANSI).

Research Materials.

# data[].attributes.field_commercial_applications.processed
Diagnostics: Meets the criteria of American National Standards Institute (ANSI).

Research Materials.

# data[].attributes.field_competitive_advantages.value
Diagnostics: Dialysis microplate for measuring free hormone analytes such as free testosterone, free thyroxine (FT4), triiodothyronine, as well as measuring unbound drugs such as dolutegravir in diagnostic or research settings.

Public Health: Use of the dialysis microplate to provide dialysis testing services for customers.

# data[].attributes.field_competitive_advantages.processed
Diagnostics: Dialysis microplate for measuring free hormone analytes such as free testosterone, free thyroxine (FT4), triiodothyronine, as well as measuring unbound drugs such as dolutegravir in diagnostic or research settings.

Public Health: Use of the dialysis microplate to provide dialysis testing services for customers.

# data[].attributes.field_licensingcontact_hrefs[]
dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio.

# data[].attributes.field_licensingcontact_htmls[]
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

# data[].attributes.field_licensing_contacts[].value
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/551,965
Filed on 2024-02-09
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/551,965
Filed on 2024-02-09
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/014980
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/014980
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/551,965
Filed on 2024-02-09
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/014980
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_technology_names[]
48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio

# data[].attributes.title
T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias

# data[].attributes.body.value
Description of Technology:

CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistance mechanisms as they use distinct target recognition mechanism. TCRs instead recognize epitopes derived from proteins processed intracellularly and presented in the context of Human Leukocyte Antigens (HLA), enabling detection of broad antigens inaccessible to antibodies or CAR-T’s – including neoantigens, cancer germline antigens, and intracellular viral oncoproteins.

Investigators at the National Cancer Institute (NCI) developed a TCR recognizing a CD22-derived epitope presented in context of the highly prevalent HLA-A*02:01. The TCR was not cross-reactive against unintended target antigens. T cells expressing the TCR (CD22 TCR-T cells) show anti-tumor activity at clinically-relevant doses without causing systemic cytokine elevation in pre-clinical, in vivo models. The inventors are translating their findings into the clinic.

NCI seeks parties interested in licensing and/or collaborations to further develop this technology.

Potential Commercial Applications:

Autologous adoptive cell therapy for patients with B-cell malignancies such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

Off-the-shelf, allogeneic adoptive cell therapy for patients will B-cell malignancies.

Therapy alternative for patients with CD22-expressing malignancies that are resistant to antibody-based treatment, including chimeric antigen receptor (CAR)-based adoptive cell therapy.

Competitive Advantages:

Clinical stage asset with an established market need and regulatory path – following the Accelerated Approvals of inotuzumab ozogamicin (Aucatzyl) in 2017 and afamitresgene autoleucel (Tecelra) in 2024.

T cells engineered to express the CD22 TCR clear leukemia at clinically-relevant doses without causing systemic cytokine elevation.

TCR is highly specific to human CD22 and is expected to recognize its target under conditions that involve loss or modulation of cell surface expression.

TCR is restricted by the highly prevalent HLA A*02:01 allele, which has an approximate frequency of up to 43% within the United States population.

# data[].attributes.body.processed
Description of Technology:

CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistance mechanisms as they use distinct target recognition mechanism. TCRs instead recognize epitopes derived from proteins processed intracellularly and presented in the context of Human Leukocyte Antigens (HLA), enabling detection of broad antigens inaccessible to antibodies or CAR-T’s – including neoantigens, cancer germline antigens, and intracellular viral oncoproteins.

Investigators at the National Cancer Institute (NCI) developed a TCR recognizing a CD22-derived epitope presented in context of the highly prevalent HLA-A*02:01. The TCR was not cross-reactive against unintended target antigens. T cells expressing the TCR (CD22 TCR-T cells) show anti-tumor activity at clinically-relevant doses without causing systemic cytokine elevation in pre-clinical, in vivo models. The inventors are translating their findings into the clinic.

NCI seeks parties interested in licensing and/or collaborations to further develop this technology.

Potential Commercial Applications:

Autologous adoptive cell therapy for patients with B-cell malignancies such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

Off-the-shelf, allogeneic adoptive cell therapy for patients will B-cell malignancies.

Therapy alternative for patients with CD22-expressing malignancies that are resistant to antibody-based treatment, including chimeric antigen receptor (CAR)-based adoptive cell therapy.

Competitive Advantages:

Clinical stage asset with an established market need and regulatory path – following the Accelerated Approvals of inotuzumab ozogamicin (Aucatzyl) in 2017 and afamitresgene autoleucel (Tecelra) in 2024.

T cells engineered to express the CD22 TCR clear leukemia at clinically-relevant doses without causing systemic cytokine elevation.

TCR is highly specific to human CD22 and is expected to recognize its target under conditions that involve loss or modulation of cell surface expression.

TCR is restricted by the highly prevalent HLA A*02:01 allele, which has an approximate frequency of up to 43% within the United States population.

# data[].attributes.field_collaboration_description.value
Researchers at the NCI seek licensing and/or co-development research collaborations for a T-cell receptor (TCR) that specifically targets an HLA-A*02:01-restricted CD22 Epitope

# data[].attributes.field_collaboration_description.processed
Researchers at the NCI seek licensing and/or co-development research collaborations for a T-cell receptor (TCR) that specifically targets an HLA-A*02:01-restricted CD22 Epitope

# data[].attributes.field_keywords[]
Relapsed / refractory B-Lymphoid Malignancies

# data[].attributes.field_licensingcontact_hrefs[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].value
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/016561
Filed on 2022-02-16
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/016561
Filed on 2022-02-16
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/149,795
Filed on 2021-02-16
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/149,795
Filed on 2021-02-16
Status: Abandoned

# data[].attributes.field_patents[].value
Canada
National Stage 3207989
Filed on 2023-08-10
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3207989
Filed on 2023-08-10
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/277,521
Filed on 2023-08-16
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/277,521
Filed on 2023-08-16
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 22709092.5
Filed on 2023-09-13
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 22709092.5
Filed on 2023-09-13
Status: Pending

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/016561
Filed on 2022-02-16
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/149,795
Filed on 2021-02-16
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3207989
Filed on 2023-08-10
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/277,521
Filed on 2023-08-16
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 22709092.5
Filed on 2023-09-13
Status: Pending

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_publications[].value
Nguyen KA, et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. (PMID: 40203088)

# data[].attributes.field_publications[].processed
Nguyen KA, et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. (PMID: 40203088)

# data[].attributes.field_related_inventions[].processed
E-152-2020

# data[].attributes.field_technology_names[]
Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD22 Epitope